```
=> d his

     (FILE 'HOME' ENTERED AT 07:37:26 ON 08 APR 2004)
               SET COST OFF

     FILE 'REGISTRY' ENTERED AT 07:37:36 ON 08 APR 2004
L1        718493 S [NDQS] [VIL] [RK] [VILF]/SQSP
L2        718352 S L1 NOT MULTICHAIN/NTE
               E FQGVLQNVRFVF/SQEP
L3             2 S E3
               E FRGCVRNLRLSR/SQEP
L4             1 S E3
L5        718490 S L1 NOT L3,L4
L6           859 S ^.{0,6}[NDQS] [VIL] [RK] [VILF] .{0,3}^/SQSP
L7           856 S L6 NOT L3,L4
L8           854 S L7 NOT MULTICHAIN/NTE
L9             2 S L7 NOT L8
               SAV L6 HADDAD030/A

     FILE 'HCAPLUS' ENTERED AT 07:41:16 ON 08 APR 2004
L10          523 S L8
               E ROBERTS D/AU
L11          218 S E3,E14
L12          215 S E85,E88,E100-E102
               E KRUTZSCH H/AU
L13          119 S E3-E7
L14            2 S L10 AND L11-L13
L15           13 S L10 AND INTEGRIN
L16         1073 S INTEGRIN(L)(ALPHA3 OR ALPHA 3)(L)(BETA1 OR BETA 1)
L17            3 S L10 AND L16
L18          219 S L10 AND PY<=1999
L19          167 S L10 AND (PRY<=1999 OR AY<=1999)
L20            2 S L18,L19 AND L16
L21            8 S L18,L19 AND L15
L22            8 S L14,L20,L21
L23          167 S L18,L19 AND P/DT
L24          119 S L23 AND US/PC
L25           67 S L24 AND US/PC.B
L26          175 S L8 (L) THU/RL
L27           23 S L8 (L) (PAC OR PKT OR DMA)/RL
L28           84 S L8 (L) BAC/RL
L29           23 S L25 AND L26-L28
L30           39 S L25 AND (PHARMACEUT? OR PHARMACOL?)/SC,SX
L31           51 S L22,L29,L30

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 07:52:55 ON 08 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)
```


FILE COVERS 1907 - 8 Apr 2004 VOL 140 ISS 15

FILE LAST UPDATED: 7 Apr 2004 (20040407/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d l31 bib abs hitrn retable tot

L31 ANSWER 1 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:203537 HCAPLUS
TI Polyepitope-based vaccines or nucleic acid vaccines for inducing cellular immune responses against cancer
IN Fikes, John; Sette, Alessandro; Sidney, John; Southwood, Scott; Chesnut, Robert; Celis, Esteban; Keogh, Elissa
PA Can.
SO U.S. Pat. Appl. Publ., 65 pp., Cont.-in-part of U.S. Ser. No. 458,297.
CODEN: USXXCO
DT **Patent**
LA English
FAN.CNT 17

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004048790	A1	20040311	US 2002-149140	20021118 <--
	CN 1118572	A	19960313	CN 1994-191364	19940304 <--
	WO 2001041788	A1	20010614	WO 2000-US33629	20001211 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2003185822	A1	20031002	US 2002-116557	20020403 <--
	US 2002160960	A1	20021031	US 2002-121415	20020411 <--
PRAI	US 1993-27146	B2	19930305 <--		
	US 1993-73205	B2	19930604 <--		
	US 1993-159184	B2	19931129 <--		
	US 1994-205713	A2	19940304 <--		
	US 1998-189702	A2	19981110 <--		
	US 1999-458297	A2	19991210 <--		
	WO 2000-US33629	W	20001211		
	US 1994-349177	A1	19941202 <--		
	US 1998-98584	B2	19980617 <--		

AB This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare p53 epitopes, and to develop epitope-based vaccines directed towards p53-bearing tumors. More specifically, this application communicates our discovery of pharmaceutical compns. and methods of use in the prevention and treatment of cancer.
IT **345202-41-7**
RL: BSU (Biological study, unclassified); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(vaccines or nucleic acid vaccines containing cytotoxic T cell or helper T cell epitopes of p53 for inducing cellular immune responses against cancer)

L31 ANSWER 2 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:176536 HCAPLUS
DN 140:216165
TI Tumor antigens of ovarian cancer and the genes encoding them and their diagnostic and therapeutic uses

IN Mitcham, Jennifer L.; King, Gordon E.; Algate, Paul A.; Fling, Steven P.; Retter, Marc W.; Fanger, Gary R.; Reed, Steven G.; Vedvick, Thomas S.; Carter, Darrick

PA Corixa Corporation, USA

SO U.S., 269 pp., Cont.-in-part of U.S. Ser. No. 636,801, abandoned.
CODEN: USXXAM

DT **Patent**

LA English

FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 6699664	B1	20040302	US 2000-667857	20000920	<--
	US 6528253	B1	20030304	US 1998-215681	19981217	<--
	US 6670463	B1	20031230	US 1998-216003	19981217	<--
	US 6488931	B1	20021203	US 1999-338933	19990623	<--
	US 6468546	B1	20021022	US 1999-404879	19990924	<--
	US 2003165504	A1	20030904	US 2001-827271	20010404	<--
	ZA 2001004510	A	20021125	ZA 2001-4510	20010531	<--
	US 2002119158	A1	20020829	US 2001-884441	20010618	<--
	WO 2002006317	A2	20020124	WO 2001-US22635	20010717	
	WO 2002006317	A3	20030703			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	EP 1349870	A2	20031008	EP 2001-954748	20010717	
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
	US 2003124140	A1	20030703	US 2002-198053	20020717	<--
	NO 2003000211	A	20030314	NO 2003-211	20030116	
PRAI	US 1998-215681	A2	19981217	<--		
	US 1998-216003	A2	19981217	<--		
	US 1999-338933	A2	19990623	<--		
	US 1999-404879	A2	19990924	<--		
	US 2000-617747	B2	20000717			
	US 2000-636801	B2	20000810			
	US 2000-667857	A2	20000920			
	US 2001-827271	A2	20010404			
	US 2001-884441	A	20010618			
	US 2001-907969	A2	20010717			
	WO 2001-US22635	W	20010717			

AB Compns. and methods for the therapy and diagnosis of cancer, such as ovarian cancer, are disclosed. Compns. may comprise one or more ovarian carcinoma proteins, immunogenic portions thereof, polynucleotides that encode such portions, or antibodies or immune system cells specific for such proteins. Such compns. may be used, for example, for the prevention and treatment of diseases such as ovarian cancer. Methods are further provided for identifying tumor antigens that are secreted from ovarian carcinomas and/or other tumors. Polypeptides and polynucleotides as provided herein may further be used for the diagnosis and monitoring of ovarian cancer. The cDNAs were identified by screening an ovarian cancer expression library with antisera, microarray technol. using a Synteni microarray, and PCR-based subtraction. Particular emphasis is given to tumor antigens O8E and O772P and their immunogenic epitopes that bind to HLA-A2.

IT **389603-31-0 389603-49-0 389603-50-3**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study);

USES (Uses)
(HLA-A2 binding peptide from tumor antigen 08E; tumor antigens of ovarian cancer and the genes encoding them and their diagnostic and therapeutic uses)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon	1996				
Anon	1997				
Anon	2000			WO 0036107	HCAPLUS
Anon	2001			WO 0116318	HCAPLUS
Anon	2001			WO 0157272	
Anon	2002			WO 0202587	HCAPLUS
Anon	2002			WO 0202624	HCAPLUS
Anon	2002			WO 0210187	HCAPLUS
Anon	2002			WO 0216429	HCAPLUS
Anon	2002			WO 0216581	HCAPLUS
Bookman		25	381	Seminars in Oncology	MEDLINE
Gillespie	1998	78	816	British Journal of C	HCAPLUS
Heller	1997	94	2150	Proc Natl Acad Sci U	HCAPLUS
Hovig, E	2001	22	345	Tumor Biology	HCAPLUS
Ishikawa	1998	5	169	DNA Res	HCAPLUS
Jin	1998	93	81	Cell	HCAPLUS
Kohler	1998	58	180	Gebrutshilfe und Fra	
Life Technologies Inc	1990		404	GIBCO GRL, Random Pr	
Ma	1998	87	1375	Journal of Pharmaceu	HCAPLUS
O'Brien, T	2001	22	348	Tumor Biology	HCAPLUS
O'Brien, T	2002	23	154	Tumor Biology	HCAPLUS
Parker	1994	152	163	The Journal of Immun	HCAPLUS
Peoples	1998	5	743	Annals of Surgical O	MEDLINE
Schena	1996	93	10614	Proc Natl Acad Sci	HCAPLUS
Schummer, M	1999	238	375	Gene	HCAPLUS
Watson	1994		63	Recombinant DNA, Cha	
Whitehouse, C	2002	269	538	Eur J Biochem	HCAPLUS
Yin	2001	276	27371	Journal of Biologica	HCAPLUS
Yin, B	2002	98	737	International Journa	HCAPLUS

L31 ANSWER 3 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:120567 HCAPLUS
DN 140:176291
TI Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
IN Raitano, Arthur B.; Morrison, Karen Jane Meyrick; Ge, Wangmao; Challita-Eid, Pia M.; Jakobovits, Aya
PA USA
SO U.S. Pat. Appl. Publ., 226 pp., Cont.-in-part of U.S. Ser. No. 547,789.
CODEN: USXXCO
DT **Patent**
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004029795	A1	20040212	US 2002-306631	20021127 <--
	US 2003147904	A1	20030807	US 2002-285045	20021030 <--
	US 2003157521	A1	20030821	US 2002-284660	20021030 <--
PRAI	US 2000-547789	A2	20000412		
	US 1999-128858P	P	19990412 <--		

AB A novel gene 024P4C12 (also designated 24P4C12) and its encoded protein, and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in cancers of the bladder, ovary, breast, uterus, and stomach. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic, and/or

therapeutic target for cancer. The 24P4C12 protein functions as a choline transporter, and is shown to be involved in transcription regulation, tumor progression, angiogenesis, and adhesion. Its gene is located on chromosome 6p21.3, and expression enhances proliferation of 3T3 and PC3 cells as well as enhancing tumor growth in SCID mice. The 24P4C12 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 24P4C12 can be used in active or passive immunization. Antigenicity profiles and candidate T cell and B cell peptides with binding specificity for HLA Class I and Class II antigens are provided.

IT **651750-99-1 651751-00-7 651752-17-9 651758-85-9 651760-29-1 651760-30-4 651760-31-5**
RL: PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(immunogenic peptide; nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer)

L31 ANSWER 4 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:113473 HCAPLUS
DN 140:180121
TI Hepatitis B vaccines comprising T cell epitopes derived from envelope, polymerase, protein X or nucleocapsid core regions of HBV
IN Sette, Alessandro; Sidney, John; Southwood, Scott; Vitiello, Maria A.; Livingston, Brian D.; Celis, Esteban; Kubo, Ralph T.; Grey, Howard M.; Chesnut, Robert W.
PA Epimmune Inc., USA
SO U.S., 73 pp., Cont.-in-part of U.S. Ser. No. 189,702.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 17

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	US 6689363	B1	20040210		US 1999-239043	19990127	<--
	EP 1018344	A2	20000712		EP 2000-102538	19920826	<--
	EP 1018344	A3	20000920				
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE						
	US 6037135	A	20000314		US 1993-159339	19931129	<--
	US 6419931	B1	20020716		US 1994-197484	19940216	<--
	CN 1118572	A	19960313		CN 1994-191364	19940304	<--
	US 2003152580	A1	20030814		US 1994-344824	19941123	<--
	US 2003185822	A1	20031002		US 2002-116557	20020403	<--
	US 2002160960	A1	20021031		US 2002-121415	20020411	<--
	JP 2004075693	A2	20040311		JP 2003-391442	20031120	<--
PRAI	US 1992-827682	B2	19920129	<--			
	US 1992-874491	B2	19920427	<--			
	US 1992-926666	B2	19920807	<--			
	US 1992-935811	B2	19920826	<--			
	US 1993-27146	B2	19930305	<--			
	US 1993-27746	B2	19930305	<--			
	US 1993-73205	B2	19930604	<--			
	US 1993-103396	B2	19930806	<--			
	US 1993-159184	B2	19931129	<--			
	US 1993-159339	A2	19931129	<--			
	US 1994-197484	A2	19940216	<--			
	US 1994-205713	A2	19940304	<--			
	US 1994-278634	B2	19940721	<--			
	US 1994-344824	A2	19941123	<--			
	US 1994-347610	A2	19941201	<--			
	US 1995-461603	A1	19950605	<--			
	US 1996-13363P	P	19960313	<--			

US 1997-820360	A2	19970312	<--
US 1997-978291	A2	19971125	<--
US 1998-189702	A2	19981110	<--
US 1991-749568	A	19910826	<--
EP 1992-307764	A3	19920826	<--
JP 1993-504664	A3	19920826	<--
US 1994-349177	A1	19941202	<--
US 1998-98584	B2	19980617	<--

AB This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to develop epitope-based vaccines directed towards HBV. The antigen is envelope, polymerase, protein X or nucleocapsid core regions of HBV; and the T cell epitopes bind to at least one MHC class I HLA allele comprising HLA-A1, A2, A3, A24, B7, B27, B44, B58, B62, A11, A2.1, A*3301, A*3101, A*6801, B*0702, B*3501, B51, B*5301, or B5401 motif. More specifically, this application communicates our discovery of pharmaceutical compns. and methods of use in the prevention and treatment of HBV infection.

IT **404946-49-2**
RL: BSU (Biological study, unclassified); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(hepatitis B vaccines comprising T cell epitopes derived from envelope, polymerase, protein X or nucleocapsid core regions of HBV)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Alexander	1998	18/2	79	Immunologic Research	
Alexander	1988	18	79	Immunological Resear	
Alexander	1997	159	4753	The Journal of Immun	HCAPLUS
Ando	1993	178	1541	J Exp Med	HCAPLUS
Anon	1991			EP 0429816 A1	HCAPLUS
Anon	1992			EP 0469281 A1	HCAPLUS
Anon	1992			EP 0491077 A1	HCAPLUS
Anon	1993			WO 9303753	HCAPLUS
Anon	1993			WO 9303764	HCAPLUS
Anon	1994			WO 9403205	HCAPLUS
Anon	1994			WO 9419011	HCAPLUS
Anon	1994			WO 9420127	HCAPLUS
Anon	1995			WO 9503777	HCAPLUS
Anon	1995			WO 9522317	HCAPLUS
Barnaba	1990	345	258	Nature	HCAPLUS
Bertoletti	1993	67	2376	Journal of Virology	HCAPLUS
Bertoletti	1994	369	407	Nature	HCAPLUS
Bertoletti	1991	88	10445	Proc Natl Acad Sci U	HCAPLUS
Bertoni	1997	100	503	J Clin Invest	HCAPLUS
Bhatnagar	1982	79	4400	Proc Natl Acad Sci U	HCAPLUS
Borras-Cuesta	1987	17	1213	Eur J Immunol	HCAPLUS
Celis	1988	140	1808	The Journal of Immun	HCAPLUS
Chisari	1998			US 5780036 A	HCAPLUS
Chisari	1998			US 5788969 A	HCAPLUS
Chisari	1998			US 5840303 A	HCAPLUS
Chisari	1999			US 5932224 A	HCAPLUS
Chisari	2001			US 6235288 B1	HCAPLUS
Chisari	1995	13	29	Annu Rev Immunol	HCAPLUS
Compugen Ltd	2001			Sequence Search Repo	
Del Guercio	1995	154	685	The Journal of Immun	HCAPLUS
Deres	1989	342	561	Nature	HCAPLUS
Fayolle	1991	147	4069	The Journal of Immun	MEDLINE
Ferrari	1991	88	214	J Clin Invest	HCAPLUS
Fujii	1983		215	Peptide Chemistry	HCAPLUS
Galibert	1984			US 4428941 A	HCAPLUS
Hayashi	1988	36	4993	Chem Pharm Bull	HCAPLUS
Henry, J	1991		785	Clinical & Laborator	

Hopp	1984	21	13	Molecular Immunology	HCAPLUS
Ishioka	1990	90	7	Vaccines	
Kondo	1995	155	4307	The Journal of Immun	HCAPLUS
Kubo	2000			US 6037135 A	HCAPLUS
Lerner	1981	78	3403	Proc Natl Acad Sci U	HCAPLUS
Machida	1991			US 5019386 A	
Milich	1986			US 4599230 A	HCAPLUS
Milich	1986			US 4599231 A	HCAPLUS
Milich	1990	3	85	Peptide Research	HCAPLUS
Milich	1987	139	1223	The Journal of Immun	HCAPLUS
Nayersina	1993	150	4659	The Journal of Immun	HCAPLUS
Neurath	1991			US 5039522 A	HCAPLUS
Penna	1991	174	1565	J Exp Med	HCAPLUS
Penna	1992	66	1193	Journal of Virology	HCAPLUS
Reherbaum	1995	181	1047	The Journal of Exper	
Ruppert	1993	74	929	Cell	HCAPLUS
Rutter	1993			US 5196194 A	HCAPLUS
Sallberg	1991	28	719	Molecular Immunology	MEDLINE
Sette	1994	153	5586	The Journal of Immun	HCAPLUS
Sette	1999			U S patent applicati	
Shimizu	1998	161	4520	The Journal of Immun	HCAPLUS
Sidney	1996	45	79	Human Immunology	HCAPLUS
Sidney	1996	157	3480	The Journal of Immun	HCAPLUS
Thornton	1989			US 4818527 A	HCAPLUS
Thornton	1989			US 4882145 A	HCAPLUS
Thornton	1992			US 5143726 A	HCAPLUS
Toes	1998	160	4449	Journal of Immunolog	HCAPLUS
Vitiello	1995	95	341	J Clin Invest	HCAPLUS
Vyas	1991			US 5017558 A	HCAPLUS
Wakita	1990	47	149	Digestion	HCAPLUS

L31 ANSWER 5 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:3572 HCAPLUS
DN 140:82214
TI Specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases
IN Hogan, Patrick G.; Rao, Anjana; Aramburu, Jose; Roehrl, Michael H. A.; Wagner, Gerhard; Kang, Sunghyun
PA USA
SO U.S. Pat. Appl. Publ., 73 pp., Cont.-in-part of U.S. Ser. No. 66,151.
CODEN: USXXCO
DT **Patent**
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE
PI	US 2004002117	A1	20040101		US 2003-358052	20030204 <--
	US 2002132300	A1	20020919		US 2002-66151	20020131 <--
PRAI	US 1998-74467P	P	19980212	<--		
	US 1999-248620	B1	19990211	<--		
	US 2002-66151	A2	20020131			

OS MARPAT 140:82214
AB The present invention relates to isolated peptide fragments of the conserved regulatory domain of NFAT protein capable of inhibiting protein-protein interaction between calcineurin and NFAT, or a biol. active analog thereof. Isolated polynucleotides and gene therapy vectors encoding such peptide fragments are also described. In addition, methods for treating immune-related diseases or conditions and methods for high throughput screening of candidate agents are described. Pharmaceutical compns. are also provided.
IT **238087-49-5 238087-53-1 238087-55-3**
238087-60-0 238087-65-5
RL: PRP (Properties)

(unclaimed sequence; specific inhibitors of NFAT activation by calcineurin and their use in treating immune-related diseases)

L31 ANSWER 6 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:3560 HCAPLUS
DN 140:72110
TI Retroviral self-inactivating vectors vectors comprising chimeric genes for use in drug screening
IN Lorens, James B.; Ferrick, David A.
PA USA
SO U.S. Pat. Appl. Publ., 57 pp., Cont.-in-part of U.S. Ser. No. 133,973.
CODEN: USXXCO
DT **Patent**
LA English
FAN.CNT 7

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	US 2004002056	A1	20040101		US 2002-151750	20020515	<--
	US 2002123076	A1	20020905		US 2001-963206	20010925	<--
	US 2002168649	A1	20021114		US 2001-966976	20010927	<--
	US 2003149254	A1	20030807		US 2002-133973	20020424	<--
PRAI	US 1998-76624	A3	19980512	<--			
	US 1999-164592P	P	19991110	<--			
	US 1999-165189P	P	19991112	<--			
	US 2000-710058	A2	20001110				
	US 2000-712821	A3	20001113				
	US 2001-290287P	P	20010510				
	US 2001-963206	A1	20010925				
	US 2001-963247	A1	20010925				
	US 2001-966976	A2	20010927				
	US 2002-133973	A2	20020424				

AB The present invention provides retroviral vectors comprising fusion nucleic acids useful for expressing a plurality of sep. gene products and methods of screening for candidate bioactive agents that alter the phenotype of a cell. Specifically, the retroviral vectors comprise chimeric genes comprising a promoter, different first gene of interest, separation sequence, and second gene of interest. The separation sequence provides a basis for producing sep. protein products encoded by the genes of interest, which may comprise reporter genes or selection genes. In another aspect the gene of interest comprises a nucleic acid encoding a dominant effector protein. Expression of the dominant effector protein alters the phenotype of the cell, which are then useful in drug screening.
IT **245759-06-2 475270-13-4**
RL: PRP (Properties)
(unclaimed sequence; retroviral self-inactivating vectors vectors comprising chimeric genes for use in drug screening)

L31 ANSWER 7 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:950450 HCAPLUS
DN 140:19794
TI Methods for the early diagnosis of ovarian cancer by determining expression of stratum corneum chymotryptic enzyme (SCCE)
IN O'Brien, Timothy J.; Cannon, Martin J.; Santin, Alessandro
PA USA
SO U.S. Pat. Appl. Publ., 61 pp., Cont.-in-part of U.S. Ser. No. 918,243.
CODEN: USXXCO
DT **Patent**
LA English
FAN.CNT 12

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 2003223973	A1	20031204	US 2003-372521	20030221	<--

	US 6303318	B1	20011016	US 1998-39211	19980314 <--
	US 6294344	B1	20010925	US 2000-502600	20000211 <--
	US 2002146708	A1	20021010	US 2001-905083	20010713 <--
	US 2002142317	A1	20021003	US 2001-918243	20010730 <--
	US 6627403	B2	20030930		
PRAI	US 1997-41404P	P	19970319 <--		
	US 1998-39211	A2	19980314 <--		
	US 2000-502600	A3	20000211		
	US 2001-905083	A2	20010713		
	US 2001-918243	A2	20010730		

AB The present invention discloses the protease stratum corneum chymotryptic enzyme (SCCE) is specifically over-expressed in ovarian and other malignancies. A number of SCCE peptides can induce immune responses to SCCE, thereby demonstrating the potential of these peptides in monitoring and the development of immunotherapies for ovarian and other malignancies. The invention provides methods of vaccinating an individual against SCCE or produce immune-activated cells directed toward SCCE by inoculating an individual with an expression vector encoding a SCCE protein or a fragment thereof. The invention also provides methods of inhibiting expression of SCCE in a cell by introducing into a cell a vector encoding an antisense SCCE RNA or an antibody that binds the SCCE protein.

IT **355838-88-9 355839-03-1 355839-23-5**
RL: PRP (Properties)
(unclaimed sequence; methods for the early diagnosis of ovarian cancer by determining expression of stratum corneum chymotryptic enzyme (SCCE))

L31 ANSWER 8 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:892099 HCAPLUS
DN 139:376231
TI The 101P3A11 or PHOR-1 gene showing aberrant expression in cancers and the gene product and their use in the diagnosis and treatment of cancer
IN Jakobovits, Aya; Faris, Mary; Raitano, Arthur B.; Morrison, Robert Kendall; Saffran, Douglas; Ge, Wangmao; Challita-Eid, Pia M.
PA USA
SO U.S. Pat. Appl. Publ., 244 pp., Cont.-in-part of U.S. Ser. No. 17,666.
CODEN: USXXCO
DT **Patent**
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003213004	A1	20031113	US 2002-147368	20020515 <--
	US 2003091562	A1	20030515	US 2001-1469	20011031 <--
PRAI	US 2001-291118P	P	20010515		
	US 2001-1469	A1	20011031		
	US 2001-17666	A2	20011214		
	US 1999-157902P	P	19991005 <--		
	US 2000-680728	A2	20001005		

AB A novel gene (designated 101P3A11 or PHOR-1) and its encoded, and variants thereof, are described wherein 101P3A11 exhibits restricted tissue-specific expression in normal adult tissue, and is aberrantly overexpressed in various cancers. Gene 101P3A11 comprises 3 exons and its protein product exhibits sequence homol. with G protein-coupled receptors. One splice variant, and 6 single nucleotide polymorphisms are identified. Consequently, 101P3A11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 101P3A11 gene or fragment thereof, or its encoded protein, or variants thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 101P3A11 can be used in active or passive immunization.

IT **475163-20-3 475163-95-2 475164-71-7**
475167-39-6 475167-69-2 475172-00-0
475174-36-8 475176-26-2
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP

(Properties); **THU (Therapeutic use)**; BIOL (Biological study);
USES (Uses)
(amino acid sequence, epitope of gene PHOR-1 protein; 101P3A11 or PHOR-1 gene showing aberrant expression in cancers and gene product and their use in diagnosis and treatment of cancer)

L31 ANSWER 9 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:785255 HCAPLUS
DN 139:302999
TI Differentially expressed sequences and proteins for use in therapy and diagnosis of human prostate cancer
IN Xu, Jiangchun; Dillon, Davin C.; Mitcham, Jennifer L.; Harlocker, Susan L.; Jiang, Yuqiu; Kalos, Michael D.; Fanger, Gary R.; Retter, Marc W.; Stolk, John A.; Day, Craig H.; Vedvick, Thomas S.; Carter, Darrick; Li, Samuel X.; Wang, Aijun; Skeiky, Yasir A. W.; Hepler, William T.; Henderson, Robert A.
PA Corixa Corporation, USA
SO U.S., 79 pp., Cont.-in-part of U.S. Ser. No. 679,426.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 28

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 6630305	B1	20031007	US 2000-685166	20001010	<--
	US 6329505	B1	20011211	US 1999-439313	19991112	<--
	US 6512094	B1	20030128	US 2000-593793	20000613	<--
	US 6620922	B1	20030916	US 2000-636215	20000810	<--
	US 2002022248	A1	20020221	US 2001-759143	20010112	<--
	US 2002051977	A1	20020502	US 2001-780669	20010209	<--
	WO 2001073032	A2	20011004	WO 2001-US9919	20010327	
	WO 2001073032	A3	20030313			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
	AU 2001049549	A5	20011008	AU 2001-49549	20010327	
	EP 1311673	A2	20030521	EP 2001-922786	20010327	
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
	JP 2004504808	T2	20040219	JP 2001-570749	20010327	
	US 2002193296	A1	20021219	US 2001-895814	20010629	<--
	US 2002183251	A1	20021205	US 2001-12896	20011210	<--
	US 2003157089	A1	20030821	US 2002-144678	20020509	<--
	US 2003185830	A1	20031002	US 2002-294025	20021112	<--
PRAI	US 1999-439313	A2	19991112	<--		
	US 1999-443686	B2	19991118	<--		
	US 2000-483672	A2	20000114			
	US 2000-536857	B2	20000327			
	US 2000-510737	A2	20000501			
	US 2000-568100	A2	20000509			
	US 2000-593793	A2	20000613			
	US 2000-605783	A2	20000627			
	US 2000-636215	A2	20000810			
	US 2000-651236	A2	20000829			
	US 2000-657279	A2	20000906			
	US 2000-679426	A2	20001002			
	US 1997-806099	B2	19970225	<--		

US 1997-904804	A2	19970801	<--
US 1998-20956	A2	19980209	<--
US 1998-30607	A2	19980225	<--
WO 1998-US3492	A2	19980225	<--
US 1998-115453	A2	19980714	<--
US 1998-159812	A2	19980923	<--
US 1999-232149	A2	19990115	<--
US 1999-288946	A2	19990409	<--
US 1999-352616	A2	19990713	<--
WO 1999-US15838	A2	19990714	<--
US 2000-570737	A2	20000512	
US 2000-685166	A2	20001010	
US 2000-709729	A2	20001109	
US 2001-759143	A2	20010112	
US 2001-780669	A2	20010209	
WO 2001-US9919	W	20010327	
US 2001-852911	A2	20010509	
US 2001-895814	A2	20010629	
US 2001-12896	A2	20011210	
US 2002-144678	A2	20020509	

AB Prostate-specific expressed genes (cDNA) and their encoded proteins useful for the therapy and diagnosis of cancer, particularly prostate cancer, are identified by conventional and PCR-based hybridization subtraction, electronic subtraction, and microarray anal. of cDNAs from a human prostate tumor cDNA library. Illustrative compns. comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen-presenting cells that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compns. are useful, for example, in the diagnosis prevention and/or treatment of diseases, particularly prostate cancer.

IT **350473-94-8 350473-96-0**
RL: PRP (Properties)
(unclaimed sequence; differentially expressed sequences and proteins for use in therapy and diagnosis of human prostate cancer)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Ahn	1993	3	283	Nature Genetics	HCAPLUS
Alexeyev	1995	160	63	Gene	HCAPLUS
Anon	1989			EP 317141 A2	
Anon	1993			WO 9314755	HCAPLUS
Anon	1993			WO 9325224	HCAPLUS
Anon	1994			WO 9409820	HCAPLUS
Anon	1995			EP 652014 A1	
Anon	1995			WO 9504548	HCAPLUS
Anon	1995			WO 9514772	HCAPLUS
Anon	1995			WO 9530758	HCAPLUS
Anon	1996			WO 9621671	HCAPLUS
Anon	1997			WO 9733909	HCAPLUS
Anon	1998				
Anon	1998				
Anon	1998				
Anon	1998			WO 9812302	HCAPLUS
Anon	1998			WO 9817687	HCAPLUS
Anon	1998			WO 9820117	HCAPLUS
Anon	1998			WO 9831799	HCAPLUS
Anon	1998			WO 9837039	HCAPLUS
Anon	1998			WO 9837093	HCAPLUS
Anon	1998			WO 9837418	HCAPLUS
Anon	1998			WO 9838310	HCAPLUS
Anon	1998			WO 9839446	HCAPLUS

Anon	1998			WO 9845435	HCAPLUS
Anon	1998			WO 9850567	HCAPLUS
Anon	1999				
Anon	1999				
Anon	1999			WO 9906548	HCAPLUS
Anon	1999			WO 9906552	HCAPLUS
Anon	1999			WO 9925825	HCAPLUS
Anon	1999			WO 9931236	HCAPLUS
Anon	1999			WO 9967384	HCAPLUS
Anon	2000			WO 0004149	HCAPLUS
Anon	2000			WO 0073801	HCAPLUS
Anon	2001			WO 0125272	HCAPLUS
Anon	2001			WO 0134802	HCAPLUS
Anon	2001			WO 0151633	HCAPLUS
Berthon	1998	62	1416	Am J Hum Genet	HCAPLUS
Blok	1995	26	213	The Prostate	HCAPLUS
Busselmakers	2000				
Busselmakers	2000				
Cawthon	1991	9	446	Genomics	HCAPLUS
Chu	1997	186	1623	J Exp Med	HCAPLUS
Coleman	1989		465	Fundamental Immunolo	
Duerst				DE 19649207 C1	HCAPLUS
El-Shirbiny	1994	31	99	Advances In Clinical	HCAPLUS
Ezzell, C	1995	7	46	The Journal of NIH R	
Gibco Brl	1990			GIBCO BRL Catalogue	
Hara	1994	84	189	Blood	HCAPLUS
Harris	1995	6	1125	J Am Soc of Nephrol	HCAPLUS
Hillier	1995				
Hillier	1997				
Hillier	1997				
Hudson, T	1996				
Kroger, B				EP 936270 A2	HCAPLUS
Lalvani	1997	186	859	J Exp Med	HCAPLUS
National Cancer Institu	1997				
National Cancer Institu	1997				
National Cancer Institu	1997				
National Cancer Institu	1997				
Nelson	2000				
Robson	1995	36	266	Proceeding of the Am	
Schena	1996	93	10614	Proc Natl Acad Sci U	
Schmidt-Wolf	1997	74	51	Annals of Hematology	HCAPLUS
Sherman	1992	258	815	Science	HCAPLUS
Short	1988	16	7583	Nucleic Acids Resear	HCAPLUS
Sjogren, H	1997	3	161	Immunotechnology	HCAPLUS
Smith	1996	274	1371	Science	HCAPLUS
Theobald	1995	92	11993	Proc Natl Sci USA	
Tusnady	1998	283	489	J Mol Biol	HCAPLUS
van Tsai	1998	18	65	Critical Reviews in	
Vasmatzis	1998	95	300	Proc Natl Acad Sci U	HCAPLUS
Yee	1996	157	4079	The Journal of Immun	HCAPLUS
Zitvogel	1998	4	594	Nature Medicine	HCAPLUS

L31 ANSWER 10 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:777109 HCAPLUS
DN 139:256389
TI Differentially expressed sequences and proteins for use in therapy and diagnosis of human prostate cancer
IN Xu, Jiangchun; Stolk, John A.; Kalos, Michael D.
PA Corixa Corporation, USA
SO U.S. Pat. Appl. Publ., 101 pp., Cont.-in-part of U.S. Ser. No. 144,678.
CODEN: USXXCO
DT **Patent**
LA English

FAN.CNT 28

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	US 2003185830	A1	20031002		US 2002-294025	20021112	<--
	US 6261562	B1	20010717		US 1998-20956	19980209	<--
	ZA 9801585	A	19980904		ZA 1998-1585	19980225	<--
	US 6262245	B1	20010717		US 1998-30607	19980225	<--
	US 2002090372	A1	20020711		US 1998-115453	19980714	<--
	US 6657056	B2	20031202				
	US 6613872	B1	20030902		US 1998-159812	19980923	<--
	US 6465611	B1	20021015		US 1999-232149	19990115	<--
	US 6395278	B1	20020528		US 1999-352616	19990713	<--
	US 6329505	B1	20011211		US 1999-439313	19991112	<--
	US 6512094	B1	20030128		US 2000-593793	20000613	<--
	US 6620922	B1	20030916		US 2000-636215	20000810	<--
	US 6630305	B1	20031007		US 2000-685166	20001010	<--
	US 2002022248	A1	20020221		US 2001-759143	20010112	<--
	US 2002051977	A1	20020502		US 2001-780669	20010209	<--
	US 2002193296	A1	20021219		US 2001-895814	20010629	<--
	US 2002183251	A1	20021205		US 2001-12896	20011210	<--
	US 2003157089	A1	20030821		US 2002-144678	20020509	<--
PRAI	US 1997-806099	B2	19970225	<--			
	US 1997-904804	B2	19970801	<--			
	US 1998-20956	A2	19980209	<--			
	US 1998-30607	A2	19980225	<--			
	US 1998-115453	A2	19980714	<--			
	US 1998-159812	A2	19980923	<--			
	US 1999-232149	A2	19990115	<--			
	US 1999-288946	B2	19990409	<--			
	US 1999-352616	A2	19990713	<--			
	US 1999-439313	A2	19991112	<--			
	US 1999-443686	B2	19991118	<--			
	US 2000-483672	A2	20000114				
	US 2000-536857	B2	20000327				
	US 2000-568100	A2	20000509				
	US 2000-570737	A2	20000512				
	US 2000-593793	A2	20000613				
	US 2000-605783	A2	20000627				
	US 2000-636215	A2	20000810				
	US 2000-651236	A2	20000829				
	US 2000-657279	A2	20000906				
	US 2000-679426	A2	20001002				
	US 2000-685166	A2	20001010				
	US 2000-709729	B2	20001109				
	US 2001-759143	A2	20010112				
	US 2001-780669	A2	20010209				
	US 2001-852911	B2	20010509				
	US 2001-895814	A2	20010629				
	US 2001-12896	A2	20011210				
	US 2002-144678	A2	20020509				
	WO 1998-US3492	A2	19980225	<--			
	WO 1999-US15838	A2	19990714	<--			
	US 2000-510737	A2	20000501				

AB Prostate-specific expressed genes (cDNA) and their encoded proteins useful for the therapy and diagnosis of cancer, particularly prostate cancer, are identified by conventional and PCR-based hybridization subtraction, electronic subtraction, and microarray anal. of cDNAs from a human prostate tumor cDNA library. Illustrative compns. comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen-presenting cells that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compns. are useful, for example, in the diagnosis prevention and/or treatment of diseases,

particularly prostate cancer. Particularly emphasized are tumor antigens designated P712P, P775P, and P504S, and an 11-amino acid fragment derived from P501S that contains naturally processed epitopes for at lease three class I alleles.

IT **350473-94-8 350473-96-0**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); **PAC (Pharmacological activity)**; PRP (Properties); **THU (Therapeutic use)**; ANST (Analytical study); BIOL (Biological study); USES (Uses)
(P501S epitope peptide; differentially expressed sequences and proteins for use in therapy and diagnosis of human prostate cancer)

IT **602332-65-0**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); **PAC (Pharmacological activity)**; PRP (Properties); **THU (Therapeutic use)**; ANST (Analytical study); BIOL (Biological study); USES (Uses)
(P501S peptide containing naturally processed epitopes for three class I antigens; differentially expressed sequences and proteins for use in therapy and diagnosis of human prostate cancer)

IT **475471-61-5**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); **PAC (Pharmacological activity)**; PRP (Properties); **THU (Therapeutic use)**; ANST (Analytical study); BIOL (Biological study); USES (Uses)
(epitope of P501S; differentially expressed sequences and proteins for use in therapy and diagnosis of human prostate cancer)

IT **583827-43-4**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); **PAC (Pharmacological activity)**; PRP (Properties); **THU (Therapeutic use)**; ANST (Analytical study); BIOL (Biological study); USES (Uses)
(minimal P501S epitope recognized by clone 2H2-1A12; differentially expressed sequences and proteins for use in therapy and diagnosis of human prostate cancer)

L31 ANSWER 11 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:717624 HCAPLUS
DN 139:241351
TI Human transmembrane serine protease TADG-12 overexpressed in ovarian carcinoma and diagnosis and treatment of cancer
IN O'Brien, Timothy J.
PA USA
SO U.S. Pat. Appl. Publ., 67 pp., Cont.-in-part of U. S. Ser. No. 650,371.
CODEN: USXXCO
DT **Patent**
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003170707	A1	20030911	US 2003-357175	20030203 <--
	US 6294663	B1	20010925	US 2000-518046	20000302 <--
PRAI	US 2000-518046	A3	20000302		
	US 2000-650371	A2	20000828		
	US 1999-261416	A2	19990303 <--		

AB The present invention provides a transmembrane serine protease TADG-12 (Tumor Associated Differentially-Expressed Gene 12) protein, splice variants of the TADG-12 protein and DNA fragments encoding such proteins. Specifically, disclosed are protein and cDNA sequences for TADG-12 (454 amino acids), and its truncated splicing variants TADG-12V (294 aa) and TADG-12D (344 aa). The 454-amino acid TADG-12 contains a potential transmembrane domain, an LDL receptor like domain, a scavenger receptor cysteine rich domain, and a serine protease domain. Three TADG-12 transcripts (2.4kb, 1.6kb, and 0.7kb) are identified and their tissue

distribution including their expression frequency in various carcinomas are studied. In TADG-12V truncation product, there is an addnl. 133bp insert leading to a frame shift and resulting in 42 amino acid unique peptide. The TADG-12 gene is mapped to chromosome 17. Furthermore, about 150 TADG-12 peptides are ranked based upon the predicted half-life of each peptide's binding to a particular HLA allele. Also provided are vectors and host cells capable of expressing the DNAs. The present invention further provides various methods of early detection and therapies of associated ovarian and other malignancies by utilizing the DNAs and/or proteins disclosed herein.

IT **290813-57-9 290813-83-1 290814-24-3**
RL: PRP (Properties)
(unclaimed sequence; human transmembrane serine protease TADG-12 overexpressed in ovarian carcinoma and diagnosis and treatment of cancer)

L31 ANSWER 12 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:696298 HCAPLUS
DN 139:212875
TI Tumor antigens of ovarian cancer and the genes encoding them and their diagnostic and therapeutic uses
IN Retter, Marc W.; Fanger, Gary R.
PA USA
SO U.S. Pat. Appl. Publ., 290 pp., Cont.-in-part of U.S. Ser. No. 667,857.
CODEN: USXXCO
DT **Patent**
LA English
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 2003165504	A1	20030904	US 2001-827271	20010404	<--
	US 6528253	B1	20030304	US 1998-215681	19981217	<--
	US 6670463	B1	20031230	US 1998-216003	19981217	<--
	US 6488931	B1	20021203	US 1999-338933	19990623	<--
	US 6468546	B1	20021022	US 1999-404879	19990924	<--
	US 6699664	B1	20040302	US 2000-667857	20000920	<--
	ZA 2001004510	A	20021125	ZA 2001-4510	20010531	<--
	US 2002119158	A1	20020829	US 2001-884441	20010618	<--
	WO 2002006317	A2	20020124	WO 2001-US22635	20010717	
	WO 2002006317	A3	20030703			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	EP 1349870	A2	20031008	EP 2001-954748	20010717	
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
	US 2003124140	A1	20030703	US 2002-198053	20020717	<--
	NO 2003000211	A	20030314	NO 2003-211	20030116	
PRAI	US 1998-215681	A2	19981217	<--		
	US 1998-216003	A2	19981217	<--		
	US 1999-338933	A2	19990623	<--		
	US 1999-404879	A2	19990924	<--		
	US 2000-617747	B2	20000717			
	US 2000-636801	B2	20000810			
	US 2000-667857	A2	20000920			
	US 2001-827271	A2	20010404			
	US 2001-884441	A	20010618			

US 2001-907969 A2 20010717
WO 2001-US22635 W 20010717

AB Compns. and methods for the therapy and diagnosis of cancer, such as ovarian cancer, are disclosed. Compns. may comprise one or more ovarian carcinoma proteins, immunogenic portions thereof, polynucleotides that encode such portions or antibodies or immune system cells specific for such proteins. Such compns. may be used, for example, for the prevention and treatment of diseases such as ovarian cancer. Methods are further provided for identifying tumor antigens that are secreted from ovarian carcinomas and/or other tumors. Polypeptides and polynucleotides as provided herein may further be used for the diagnosis and monitoring of ovarian cancer. The cDNAs were identified by screening an ovarian cancer expression library with antisera, Microarray technol. using a Synteni microarray, and PCR-based subtraction. Particular emphasis is given to tumor antigens 08E and 0772P and their immunogenic epitopes that bind to HLA-A2.

IT **389603-31-0 389603-49-0 389603-50-3**
RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(HLA-A2 binding peptide from tumor antigen 08E; tumor antigens of ovarian cancer and the genes encoding them and their diagnostic and therapeutic uses)

L31 ANSWER 13 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:656212 HCAPLUS
DN 139:192523
TI Differentially expressed sequences and proteins for use in therapy and diagnosis of human prostate cancer
IN Xu, Jiangchun; Dillon, Davin C.; Mitcham, Jennifer L.; Harlocker, Susan L.; Jiang, Yuqiu; Henderson, Robert A.; Kalos, Michael D.; Fanger, Gary R.; Retter, Marc W.; Stolk, John A.; Day, Craig H.; Vedvick, Thomas S.; Carter, Darrick; Li, Samuel X.; Wang, Aijun; Skeiky, Yasir A. W.; Hepler, William T.; Hural, John; McNeill, Patricia D.; Houghton, Raymond L.; Vinals y De Bassols, Carlota; Foy, Teresa M.; Watanabe, Yoshihiro; Meagher, Madeleine Joy; Deng, Ta
PA Corixa Corporation, USA
SO U.S. Pat. Appl. Publ., 99 pp., Cont.-in-part of U. S. Ser. No. 12,896.
CODEN: USXXCO
DT **Patent**
LA English
FAN.CNT 28

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 2003157089	A1	20030821	US 2002-144678	20020509	<--
	US 6261562	B1	20010717	US 1998-20956	19980209	<--
	ZA 9801585	A	19980904	ZA 1998-1585	19980225	<--
	US 6262245	B1	20010717	US 1998-30607	19980225	<--
	US 2002090372	A1	20020711	US 1998-115453	19980714	<--
	US 6657056	B2	20031202			
	US 6613872	B1	20030902	US 1998-159812	19980923	<--
	US 6465611	B1	20021015	US 1999-232149	19990115	<--
	US 6395278	B1	20020528	US 1999-352616	19990713	<--
	US 6329505	B1	20011211	US 1999-439313	19991112	<--
	US 6512094	B1	20030128	US 2000-593793	20000613	<--
	US 6620922	B1	20030916	US 2000-636215	20000810	<--
	US 6630305	B1	20031007	US 2000-685166	20001010	<--
	US 2002022248	A1	20020221	US 2001-759143	20010112	<--
	US 2002051977	A1	20020502	US 2001-780669	20010209	<--
	US 2002193296	A1	20021219	US 2001-895814	20010629	<--
	US 2002183251	A1	20021205	US 2001-12896	20011210	<--
	US 2003185830	A1	20031002	US 2002-294025	20021112	<--
PRAI	US 1997-806099	B2	19970225	<--		

US 1997-904804	B2	19970801	<--
US 1998-20956	A2	19980209	<--
US 1998-30607	A2	19980225	<--
US 1998-115453	A2	19980714	<--
US 1998-159812	A2	19980923	<--
US 1999-232149	A2	19990115	<--
US 1999-288946	B2	19990409	<--
US 1999-352616	A2	19990713	<--
US 1999-439313	A2	19991112	<--
US 1999-443686	B2	19991118	<--
US 2000-483672	A2	20000114	
US 2000-536857	B2	20000327	
US 2000-568100	A2	20000509	
US 2000-570737	A2	20000512	
US 2000-593793	A2	20000613	
US 2000-605783	A2	20000627	
US 2000-636215	A2	20000810	
US 2000-651236	A2	20000829	
US 2000-657279	A2	20000906	
US 2000-679426	A2	20001002	
US 2000-685166	A2	20001010	
US 2000-709729	B2	20001109	
US 2001-759143	A2	20010112	
US 2001-780669	A2	20010209	
US 2001-852911	B2	20010509	
US 2001-895814	A2	20010629	
US 2001-12896	A2	20011210	
WO 1998-US3492	A2	19980225	<--
WO 1999-US15838	A2	19990714	<--
US 2000-510737	A2	20000501	
US 2002-144678	A2	20020509	

AB Prostate-specific expressed genes (cDNA) and their encoded proteins useful for the therapy and diagnosis of cancer, particularly prostate cancer, are identified by conventional and PCR-based hybridization subtraction, electronic subtraction, and microarray anal. of cDNAs from a human prostate tumor cDNA library. Illustrative compns. comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen-presenting cells that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compns. are useful, for example, in the diagnosis prevention and/or treatment of diseases, particularly prostate cancer.

IT **350473-94-8 350473-96-0**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); **PAC (Pharmacological activity)**; PRP (Properties); **THU (Therapeutic use)**; ANST (Analytical study); BIOL (Biological study); USES (Uses)
(P501S epitope peptide; differentially expressed sequences and proteins for use in therapy and diagnosis of human prostate cancer)

IT **475471-61-5**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); **PAC (Pharmacological activity)**; PRP (Properties); **THU (Therapeutic use)**; ANST (Analytical study); BIOL (Biological study); USES (Uses)
(P501S epitope; differentially expressed sequences and proteins for use in therapy and diagnosis of human prostate cancer)

IT **583827-43-4**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); **PAC (Pharmacological activity)**; PRP (Properties); **THU (Therapeutic use)**; ANST (Analytical study); BIOL (Biological study); USES (Uses)
(minimal P501S epitope recognized by clone 2H2-1A12; differentially expressed sequences and proteins for use in therapy and diagnosis of

human prostate cancer)

L31 ANSWER 14 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:511849 HCAPLUS
DN 139:83962
TI Ovarian cancer-associated antigens, protein and cDNA sequences thereof, and methods for the therapy and diagnosis of ovarian cancer
IN Bangur, Chaitanya S.; Retter, Marc W.; Fanger, Gary R.; Hill, Paul
PA Corixa Corporation, USA
SO U.S. Pat. Appl. Publ., 399 pp., Cont.-in-part of U.S. Ser. No. 907,969.
CODEN: USXXCO
DT **Patent**
LA English
FAN.CNT 9

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	US 2003124140	A1	20030703		US 2002-198053	20020717	<--
	US 6528253	B1	20030304		US 1998-215681	19981217	<--
	US 6670463	B1	20031230		US 1998-216003	19981217	<--
	US 6488931	B1	20021203		US 1999-338933	19990623	<--
	US 6468546	B1	20021022		US 1999-404879	19990924	<--
	US 6699664	B1	20040302		US 2000-667857	20000920	<--
	US 2003165504	A1	20030904		US 2001-827271	20010404	<--
	ZA 2001004510	A	20021125		ZA 2001-4510	20010531	<--
	US 2002119158	A1	20020829		US 2001-884441	20010618	<--
	US 2003091580	A1	20030515		US 2001-907969	20010717	<--
PRAI	US 1998-215681	A2	19981217	<--			
	US 1998-216003	A2	19981217	<--			
	US 1999-338933	A2	19990623	<--			
	US 1999-404879	A2	19990924	<--			
	US 2000-617747	A2	20000717				
	US 2000-636801	B2	20000810				
	US 2000-667857	A2	20000920				
	US 2001-827271	A2	20010404				
	US 2001-884441	A2	20010618				
	US 2001-907969	A2	20010717				

AB Methods are provided for identifying tumor antigens that are secreted from ovarian carcinomas and/or other tumors. Proteins found in ovarian cancers but not in healthy ovaries are identified, as well as cDNAs encoding the proteins, for use in the diagnosis and treatment of cancer. The ovarian cancer-associated antigens or cDNAs encoding them may be useful in vaccines against ovarian cancer (no data). Illustrative compns. comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. Detailed characterization of ovarian cancer antigen 0772P is reported. The protein has an N-terminal domain containing a variable number of copies of variants of a repeat region and a constant C-terminal domain. It is recognized by HLA-A2 antigens. Epitope peptides of 0772P and 08E antigens are provided. Ovarian cancer associated protein 08E orthologs and corresponding cDNAs from Rhesus monkey and mouse are also provided. The disclosed compns. are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.
IT **389603-31-0 389603-49-0 389603-50-3**
RL: PRP (Properties)
(unclaimed sequence; ovarian cancer-associated antigens, protein and cDNA sequences thereof, and methods for the therapy and diagnosis of ovarian cancer)

L31 ANSWER 15 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:376140 HCAPLUS
DN 138:400391

TI Protein 101P3A41, polynucleotides, and antibodies for diagnosis, prognosis and treatment of cancer
IN Jakobovits, Aya; Raitano, Arthur B.; Afar, Daniel E. H.; Saffran, Douglas C.; Hubert, Rene S.; Faris, Mary; Challita-Eid, Pia M.
PA USA
SO U.S. Pat. Appl. Publ., 166 pp., Cont.-in-part of U.S. Ser. No. 680,728. CODEN: USXXCO
DT **Patent**
LA English
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003091562	A1	20030515	US 2001-1469	20011031 <--
WO 2002092842	A2	20021121	WO 2002-US15520	20020515

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003213004	A1	20031113	US 2002-147368	20020515 <--
PRAI US 1999-157902P	P	19991005 <--		
US 2000-680728	A2	20001005		
US 2001-291118P	P	20010515		
US 2001-1469	A	20011031		
US 2001-17666	A	20011214		

AB A novel gene, designated 101P3A11 and also referred to as PHOR-1, and its encoded protein are described. While 101P3A11 exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in prostate, colon and kidney cancers. Thus, 101P3A11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 101P3A11 gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit an immune response.
IT **475163-20-3 475163-95-2 475164-71-7**
475167-39-6 475167-69-2 475172-00-0
RL: PRP (Properties)
(unclaimed sequence; protein 101P3A41, polynucleotides, and antibodies for diagnosis, prognosis and treatment of cancer)

L31 ANSWER 16 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:98032 HCAPLUS
DN 138:148752
TI Cloning and cDNA and deduced amino acid sequences of 125 human secreted proteins
IN Rosen, Craig A.; Feng, Ping; Ruben, Steven M.; Ebner, Reinhard; Olsen, Henrik S.; Ni, Jian; Wei, Ying-Fei; Soppet, Daniel R.; Moore, Paul A.; Kyaw, Hla; Lafleur, David W.; Shi, Yanggu; Janat, Fouad; Endress, Gregory A.; Carter, Kenneth C.; Birse, Charles E.
PA USA
SO U.S. Pat. Appl. Publ., 496 pp., Cont.-in-part of U.S. Ser. No. 818,683. CODEN: USXXCO
DT **Patent**
LA English
FAN.CNT 4

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003028003	A1	20030206	US 2001-974879	20011012 <--
WO 9924836	A1	19990520	WO 1998-US23435	19981104 <--

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE,

KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,
MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	US 2003088078	A1	20030508	US 1999-305736	19990505	<--
	US 2003211472	A1	20031113	US 2001-818683	20010328	<--
	US 2004038277	A1	20040226	US 2003-621401	20030718	<--
PRAI	US 1997-64900P	P	19971107	<--		
	US 1997-64908P	P	19971107	<--		
	US 1997-64911P	P	19971107	<--		
	US 1997-64912P	P	19971107	<--		
	US 1997-64983P	P	19971107	<--		
	US 1997-64984P	P	19971107	<--		
	US 1997-64985P	P	19971107	<--		
	US 1997-64987P	P	19971107	<--		
	US 1997-64988P	P	19971107	<--		
	US 1997-66089P	P	19971117	<--		
	US 1997-66090P	P	19971117	<--		
	US 1997-66094P	P	19971117	<--		
	US 1997-66095P	P	19971117	<--		
	US 1997-66100P	P	19971117	<--		
	WO 1998-US23435	A2	19981104	<--		
	US 1999-305736	A1	19990505	<--		
	US 2000-239893P	P	20001013			
	US 2001-818683	A2	20010328			
	US 2001-974879	A1	20011012			

AB The present invention relates to 125 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

IT **495392-44-4**
RL: PRP (Properties)
(unclaimed sequence; cloning and cDNA and deduced amino acid sequences of 125 human secreted proteins)

L31 ANSWER 17 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:23361 HCAPLUS
DN 138:88641
TI Mycobacterium vaccae antigens for treating immunologically mediated skin disorders
IN Watson, James D.; Tan, Paul L. J.; Prestidge, Ross
PA N. Z.
SO U.S. Pat. Appl. Publ., 122 pp., Cont.-in-part of U.S. 6,328,978.
CODEN: USXXCO
DT **Patent**
LA English
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 2003007976	A1	20030109	US 2001-880505	20010613	<--
	US 5968524	A	19991019	US 1997-997080	19971223	<--
	US 6328978	B1	20011211	US 1999-324542	19990602	<--
PRAI	US 1997-997080	A2	19971223	<--		
	US 1999-324542	A2	19990602	<--		

AB Methods for the treatment of skin disorders, including psoriasis, atopic dermatitis, allergic contact dermatitis, alopecia areata, skin cancers, and related disorders, such as psoriatic arthritis are provided, such methods comprising administering a composition having antigenic and/or adjuvant properties. Compns. which may be usefully employed in the inventive methods include inactivated M. vaccae cells, delipidated and deglycolipidated M. vaccae cells, M. vaccae culture filtrate and compds. present in or derived therefrom, together with combinations of such compns.

IT **482668-91-7**
RL: BSU (Biological study, unclassified); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(Mycobacterium vaccae antigens for treating immunol. mediated skin disorders)

L31 ANSWER 18 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:1231 HCAPLUS
DN 138:67839
TI Neurogenesis-inducing genes
IN Mikoshiba, Katsuhiko; Aruga, Jun; Nagai, Takeharu; Nakata, Katsunori
PA The Institute of Physical and Chemical Research, Japan
SO U.S., 61 pp., Cont.-in-part of U. S. 6,277,594.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	US 6500637	B1	20021231		US 1999-342325	19990629	<--
	JP 11341985	A2	19991214		JP 1998-121456	19980430	<--
	US 6277594	B1	20010821		US 1998-172045	19980928	<--
	US 2003113773	A1	20030619		US 2002-244367	20020916	<--
PRAI	JP 1998-86979	A	19980331	<--			
	JP 1998-121456	A	19980430	<--			
	US 1998-172045	A2	19980928	<--			
	US 1999-342325	A3	19990629	<--			

AB The present invention relates to neurogenesis-inducing genes. In particular, the present invention provides neurogenesis-inducing genes coding for Zic proteins, vectors containing such genes, host cells containing such vectors, proteins produced by such host cells, antibodies raised to such proteins, and therapeutic agents or agents for gene therapy for nervous diseases.

IT **252228-07-2**
RL: PRP (Properties)
(unclaimed sequence; neurogenesis-inducing genes)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anderson	1998	392	25	Nature	
Anderson	1985			Nucleic Acid Hybridi	
Anon	1990			WO 9008832	HCAPLUS
Aruga	1999			Argua Accession No D	
Aruga	1996	172	291	Gene	HCAPLUS
Aruga	1996	271	1043	J Biol Chem	HCAPLUS
Aruga	1994	63	1880	J Neurochem	HCAPLUS
Aruga	1998	18	284	J Neurosci	HCAPLUS
Becker	1990	194	182	Methods Enzymol	
Benedyk	1994	8	105	Genes Dev	HCAPLUS
Boshart	1985	41	521	Cell	HCAPLUS
Bradley	1984	309	255	Nature	MEDLINE
Brinster	1985	82	4438	Proc Natl Acad Sci U	HCAPLUS

Chamberlin	1970	228	227	Nature	HCAPLUS
Chitnis	1995	375	761	Nature	HCAPLUS
Cimbora	1995	169	580	Dev Biol	HCAPLUS
Cohen	1972	69	2110	Proc Natl Acad Sci U	HCAPLUS
Crystal	1995	270	404	Science	HCAPLUS
Deonarain	1998	8	53	Exp Opin Ther Patent	HCAPLUS
Dijkema	1985	4	761	EMBO J	HCAPLUS
Doe	1994	24	2369	Eur J Immunol	HCAPLUS
Eck	1995		77	Goodman and Gilmans	
Erickson	1993	151	4189	J Immunol	HCAPLUS
Erlich	1989			PCR Technology	
Evans	1981	292	154	Nature	MEDLINE
Ferreiro	1994	120	3649	Development	HCAPLUS
Frade	1996	122	2497	Development	HCAPLUS
Gebbia	1997	17	305	Nature Genet	HCAPLUS
Geysen	1987			US 4708871 A	HCAPLUS
Geysen	1986	23	709	Mol Immunol	HCAPLUS
Geysen	1984	81	3998	Proc Natl Acad Sci U	HCAPLUS
Godsave	1989	134	486	Dev Biol	MEDLINE
Gorman	1982	79	6777	Proc Natl Acad Sci U	HCAPLUS
Gossler	1986	83	9065	Proc Natl Acad Sci U	HCAPLUS
Graham	1973	52	456	Virol	MEDLINE
Grunz	1989	28	211	Cell Differ Dev	MEDLINE
Hanahan	1983	166	557	J Mol Bio	HCAPLUS
Hanks	1995	269	679	Science	HCAPLUS
Harland	1991	36	685	Methods in Cell Biol	MEDLINE
Haskell	1995	40	386	Mol Reprod Dev	HCAPLUS
Hemmati-Brivanlou	1994	77	283	Cell	HCAPLUS
Hemmati-Brivanlou	1991	111	715	Development	HCAPLUS
Hinnen	1978	75	1929	Proc Natl Acad Sci U	HCAPLUS
Hogan	1986			Manipulating the Mou	
Hopwood	1989	59	893	Cell	HCAPLUS
i Altaba	1997	90	193	Cell	
Ito	1983	153	163	J Bacteriol	HCAPLUS
Jaenisch	1976	73	1260	Proc Natl Acad Sci U	MEDLINE
Jaenisch	1988	240	1468	Science	HCAPLUS
Jahner	1982	298	623	Nature	MEDLINE
Jahner	1985	82	6927	Proc Natl Acad Sci U	MEDLINE
Jones	1986	44	345	Cell	HCAPLUS
Kacian	1972	69	3038	Proc Natl Acad Sci U	HCAPLUS
Kim	1990	91	217	Gene	HCAPLUS
Kintner	1987	99	311	Development	HCAPLUS
Lamb	1993	262	713	Science	HCAPLUS
Lee	1995	268	836	Science	HCAPLUS
Maniatis	1987	236	1237	Science	HCAPLUS
Mayor	1995	121	767	Development	HCAPLUS
Miller	1995	9	190	FASEB J	HCAPLUS
Mizuseki	1998	125	579	Development	HCAPLUS
Mizushima	1990	18	5322	Nuc Acids Res	HCAPLUS
Moon	1989	1	76	Technique	HCAPLUS
Mullis	1987			US 4683195 A	HCAPLUS
Mullis	1987			US 4683202 A	HCAPLUS
Mullis	1990			US 4965188 A	HCAPLUS
Nagai	1997	182	299	Dev Biol	HCAPLUS
Nakata	1998	75	43	Mechanisms of Develo	HCAPLUS
Nakata	1997	94	11980	Proc Natl Acad Sci U	HCAPLUS
Newport	1982	30	675	Cell	HCAPLUS
Nieuwkoop	1967			Normal Table of Xeno	
Orkin	1995			Report and Recommend	
Oschwald	1991	35	399	Int J Dev Biol	HCAPLUS
Pannese	1995	121	707	Development	HCAPLUS
Pavletich	1993	261	1701	Science	HCAPLUS
Pearson	1988	85	2444	Proc Natl Acad Sci U	HCAPLUS

Robertson	1986	322	445	Nature	
Rudinger	1972			Characteristics of t	
Sambrook	1989		16.6	Molecular Cloning:A	
Sasai	1994	79	779	Cell	HCAPLUS
Sasai	1995	376	333	Nature	HCAPLUS
Shain	1996	31	185	J Biochem Biophys Me	HCAPLUS
Stewart	1987	6	383	EMBO J	HCAPLUS
Suzuki	1995	37	581	Develop Growth Diffe	HCAPLUS
Takebayashi	1997	16	384	EMBO J	HCAPLUS
Turner	1994	8	1434	Genes Dev	HCAPLUS
Turner	1982	10	3769	Nucleic Acids Res	HCAPLUS
Uetsuki	1989	264	5791	J Biol Chem	HCAPLUS
Unanue	1987	236	551	Science	HCAPLUS
Upton	1992	9	83	Mol Endocrinol	HCAPLUS
van der Putten	1985	82	6148	Proc Natl Acad Sci U	HCAPLUS
Verma	1997	389	239	Nature	HCAPLUS
Voss	1986	11	287	Trends Biochem Sci	HCAPLUS
Wagner	1989			US 4873191 A	
Wilson	1995	376	331	Nature	HCAPLUS
Witta	1995	121	721	Development	HCAPLUS
Wright	1990	109	225	Development	HCAPLUS
Wu	1989	4	560	Genomics	HCAPLUS
Yokota	1996	56	377	Cancer Res	HCAPLUS
Zimmerman	1996	86	599	Cell	HCAPLUS
Zimmerman	1993	119	221	Development	HCAPLUS

L31 ANSWER 19 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:965104 HCAPLUS
DN 138:34230
TI Differentially expressed sequences and proteins for use in therapy and diagnosis of human prostate cancer
IN Xu, Jiangchun; Dillon, Davin C.; Mitcham, Jennifer L.; Harlocker, Susan L.; Jiang, Yuqiu; Kalos, Michael D.; Fanger, Gary R.; Retter, Marc W.; Stolk, John A.; Day, Craig H.; Vedvick, Thomas S.; Carter, Darrick; Li, Samuel X.; Wang, Aijun; Skeiky, Yasir A. W.; Hepler, William T.; Henderson, Robert A.; Hural, John; Mcneill, Patricia D.; Houghton, Raymond L.; Vinals y De Bassols, Carlota; Foy, Teresa M.
PA USA
SO U.S. Pat. Appl. Publ., 89 pp., Cont.-in-part of U.S. Ser. No. 852,911.
CODEN: USXXCO
DT **Patent**
LA English
FAN.CNT 28

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002193296	A1	20021219	US 2001-895814	20010629 <--
	US 6261562	B1	20010717	US 1998-20956	19980209 <--
	ZA 9801585	A	19980904	ZA 1998-1585	19980225 <--
	US 6262245	B1	20010717	US 1998-30607	19980225 <--
	US 2002090372	A1	20020711	US 1998-115453	19980714 <--
	US 6657056	B2	20031202		
	US 6613872	B1	20030902	US 1998-159812	19980923 <--
	US 6465611	B1	20021015	US 1999-232149	19990115 <--
	US 6395278	B1	20020528	US 1999-352616	19990713 <--
	US 6329505	B1	20011211	US 1999-439313	19991112 <--
	US 6512094	B1	20030128	US 2000-593793	20000613 <--
	US 6620922	B1	20030916	US 2000-636215	20000810 <--
	US 6630305	B1	20031007	US 2000-685166	20001010 <--
	US 2002022248	A1	20020221	US 2001-759143	20010112 <--
	US 2002051977	A1	20020502	US 2001-780669	20010209 <--
	US 2002183251	A1	20021205	US 2001-12896	20011210 <--
	WO 2002089747	A2	20021114	WO 2002-US14753	20020509

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	US 2003157089	A1	20030821	US 2002-144678	20020509	<--
	US 2003185830	A1	20031002	US 2002-294025	20021112	<--
PRAI	US 1997-806099	B2	19970225	<--		
	US 1997-904804	B2	19970801	<--		
	US 1998-20956	A2	19980209	<--		
	US 1998-30607	A2	19980225	<--		
	US 1998-115453	A2	19980714	<--		
	US 1998-159812	A2	19980923	<--		
	US 1999-232149	A2	19990115	<--		
	US 1999-288946	A2	19990409	<--		
	US 1999-352616	A2	19990713	<--		
	US 1999-439313	A2	19991112	<--		
	US 1999-443686	B2	19991118	<--		
	US 2000-483672	A2	20000114			
	US 2000-536857	B2	20000327			
	US 2000-568100	A2	20000509			
	US 2000-570737	A2	20000512			
	US 2000-593793	A2	20000613			
	US 2000-605783	A2	20000627			
	US 2000-636215	A2	20000810			
	US 2000-651236	A2	20000829			
	US 2000-657279	A2	20000906			
	US 2000-679426	A2	20001002			
	US 2000-685166	A2	20001010			
	US 2000-709729	B2	20001109			
	US 2001-759143	A2	20010112			
	US 2001-780669	A2	20010209			
	US 2001-852911	A2	20010509			
	WO 1998-US3492	A2	19980225	<--		
	WO 1999-US15838	A2	19990714	<--		
	US 2000-510737	A2	20000501			
	US 2001-895814	A2	20010629			
	US 2001-12896	A	20011210			
	US 2002-144678	A2	20020509			

AB Prostate-specific expressed genes (cDNA) and their encoded proteins useful for the therapy and diagnosis of cancer, particularly prostate cancer, are identified by conventional and PCR-based hybridization subtraction, electronic subtraction, and microarray anal. of cDNAs from a human prostate tumor cDNA library. Illustrative compns. comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen-presenting cells that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compns. are useful, for example, in the diagnosis prevention and/or treatment of diseases, particularly prostate cancer.

IT **350473-94-8 350473-96-0**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); **PAC (Pharmacological activity)**; PRP (Properties); **THU (Therapeutic use)**; ANST (Analytical study); BIOL (Biological study); USES (Uses)
(P501S epitope peptide; differentially expressed sequences and proteins for use in therapy and diagnosis of human prostate cancer)

IT **475471-61-5**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic

use); **PAC (Pharmacological activity)**; PRP (Properties); **THU (Therapeutic use)**; ANST (Analytical study); BIOL (Biological study); USES (Uses)
(epitope of P501S; differentially expressed sequences and proteins for use in therapy and diagnosis of human prostate cancer)

L31 ANSWER 20 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:965020 HCAPLUS
DN 138:34228
TI Differentially expressed sequences and proteins for use in therapy and diagnosis of human prostate cancer
IN Xu, Jiangchun; Dillon, Davin C.; Mitcham, Jennifer L.; Harlocker, Susan L.; Jiang, Yuqiu; Kalos, Michael D.; Fanger, Gary R.; Retter, Marc W.; Stolk, John A.; Day, Craig H.; Vedvick, Thomas S.; Carter, Darrick; Li, Samuel X.; Wang, Aijun; Skeiky, Yasir A. W.; Hepler, William T.; Henderson, Robert A.; Hural, John; Mcneill, Patricia D.; Houghton, Raymond L.; Vinals y de Bassols, Carlota; Foy, Teresa M.
PA USA
SO U.S. Pat. Appl. Publ., 85 pp., Cont.-in-part of U.S. Ser. No. 822,827.
CODEN: USXXCO
DT **Patent**
LA English
FAN.CNT 28

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	US 2002192763	A1	20021219		US 2001-895793	20010629	<--
	US 2002081680	A1	20020627		US 2001-822827	20010328	<--
PRAI	US 2000-157455P	P	20000417				
	US 2000-679272	A2	20001004				
	US 2001-822827	A2	20010328				
	US 1999-157455P	P	19991004	<--			
	US 2001-780669	A2	20010209				

AB Prostate-specific expressed genes (cDNA) and their encoded proteins useful for the therapy and diagnosis of cancer, particularly prostate cancer, are identified by conventional and PCR-based hybridization subtraction, electronic subtraction, and microarray anal. of cDNAs from a human prostate tumor cDNA library. Illustrative compns. comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen-presenting cells that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compns. are useful, for example, in the diagnosis prevention and/or treatment of diseases, particularly prostate cancer.
IT **350473-94-8 350473-96-0**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); **PAC (Pharmacological activity)**; PRP (Properties); **THU (Therapeutic use)**; ANST (Analytical study); BIOL (Biological study); USES (Uses)
(P501S epitope peptide; differentially expressed sequences and proteins for use in therapy and diagnosis of human prostate cancer)

L31 ANSWER 21 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:928231 HCAPLUS
DN 138:1133
TI Differentially expressed sequences and proteins for use in therapy and diagnosis of human prostate cancer
IN Xu, Jiangchun; Dillon, Davin C.; Mitcham, Jennifer L.; Harlocker, Susan L.; Jiang, Yuqiu; Kalos, Michael D.; Fanger, Gary R.; Retter, Marc W.; Stolk, John A.; Day, Craig H.; Vedvick, Thomas S.; Carter, Darrick; Li, Samuel X.; Wang, Aijun; Skeiky, Yasir A. W.; Hepler, William T.; Henderson, Robert A.; Hural, John; Mcneill, Patricia D.; Houghton, Raymond L.; Vinals, Y. De Bassols Carlota; Foy, Teresa M.; Watanabe, Yoshihiro; Meagher, Madeleine Joy

PA Corixa Corporation, USA
SO U.S. Pat. Appl. Publ., 97 pp., Cont.-in-part of U.S. Ser. No. 895,814.
CODEN: USXXCO
DT **Patent**
LA English
FAN.CNT 28

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 2002183251	A1	20021205	US 2001-12896	20011210	<--
	US 6261562	B1	20010717	US 1998-20956	19980209	<--
	ZA 9801585	A	19980904	ZA 1998-1585	19980225	<--
	US 6262245	B1	20010717	US 1998-30607	19980225	<--
	US 2002090372	A1	20020711	US 1998-115453	19980714	<--
	US 6657056	B2	20031202			
	US 6613872	B1	20030902	US 1998-159812	19980923	<--
	US 6465611	B1	20021015	US 1999-232149	19990115	<--
	US 6395278	B1	20020528	US 1999-352616	19990713	<--
	US 6329505	B1	20011211	US 1999-439313	19991112	<--
	US 6512094	B1	20030128	US 2000-593793	20000613	<--
	US 6620922	B1	20030916	US 2000-636215	20000810	<--
	US 6630305	B1	20031007	US 2000-685166	20001010	<--
	US 2002022248	A1	20020221	US 2001-759143	20010112	<--
	US 2002051977	A1	20020502	US 2001-780669	20010209	<--
	US 2002193296	A1	20021219	US 2001-895814	20010629	<--
	WO 2002089747	A2	20021114	WO 2002-US14753	20020509	
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
	US 2003157089	A1	20030821	US 2002-144678	20020509	<--
	US 2003185830	A1	20031002	US 2002-294025	20021112	<--
PRAI	US 1997-806099	B2	19970225	<--		
	US 1997-904804	B2	19970801	<--		
	US 1998-20956	A2	19980209	<--		
	US 1998-30607	A2	19980225	<--		
	US 1998-115453	A2	19980714	<--		
	US 1998-159812	A2	19980923	<--		
	US 1999-232149	A2	19990115	<--		
	US 1999-288946	A2	19990409	<--		
	US 1999-352616	A2	19990713	<--		
	US 1999-439313	A2	19991112	<--		
	US 1999-443686	B2	19991118	<--		
	US 2000-483672	A2	20000114			
	US 2000-536857	B2	20000327			
	US 2000-568100	A2	20000509			
	US 2000-570737	A2	20000512			
	US 2000-593793	A2	20000613			
	US 2000-605783	A2	20000627			
	US 2000-636215	A2	20000810			
	US 2000-651236	A2	20000829			
	US 2000-657279	A2	20000906			
	US 2000-679426	A2	20001002			
	US 2000-685166	A2	20001010			
	US 2000-709729	B2	20001109			
	US 2001-759143	A2	20010112			
	US 2001-780669	A2	20010209			
	US 2001-852911	A2	20010509			

US 2001-895814 A2 20010629
WO 1998-US3492 A2 19980225 <--
WO 1999-US15838 A2 19990714 <--
US 2000-510737 A2 20000501
US 2001-12896 A 20011210
US 2002-144678 A2 20020509

AB Prostate-specific expressed genes (cDNA) and their encoded proteins useful for the therapy and diagnosis of cancer, particularly prostate cancer, are identified by conventional and PCR-based hybridization subtraction, electronic subtraction, and microarray anal. of cDNAs from a human prostate tumor cDNA library. Illustrative compns. comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen-presenting cells that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compns. are useful, for example, in the diagnosis prevention and/or treatment of diseases, particularly prostate cancer.

IT **475471-61-5**
RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); **PAC (Pharmacological activity)**; PRP (Properties); **THU (Therapeutic use)**; ANST (Analytical study); BIOL (Biological study); USES (Uses)
(P501S epitope; differentially expressed sequences and proteins for use in therapy and diagnosis of human prostate cancer)

IT **350473-94-8 350473-96-0**
RL: PRP (Properties)
(unclaimed sequence; differentially expressed sequences and proteins for use in therapy and diagnosis of human prostate cancer)

L31 ANSWER 22 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:845503 HCAPLUS
DN 137:347552
TI Cloning and cDNA and deduced amino acid sequences of 94 human secreted proteins
IN Ruben, Steven M.; Ni, Jian; Rosen, Craig A.; Wei, Ying-Fei; Young, Paul; Florence, Kimberly; Soppet, Daniel R.; Brewer, Laurie A.; Endress, Gregory A.; Carter, Kenneth C.; Mucenski, Michael; Ebner, Reinhard; Lafleur, David W.; Olsen, Henrik; Shi, Yanggu; Moore, Paul A.; Komatsoulis, George
PA Human Genome Sciences, Inc., USA
SO U.S., 157 pp., Cont.-in-part of Appl. No. PCT/US99/13418.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 42

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6475753	B1	20021105	US 1999-461325	19991214 <--
	WO 9966041	A1	19991223	WO 1999-US13418	19990615 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2003044851	A1	20030306	US 2001-12542	20011212 <--
	US 6627741	B2	20030930		
	US 2003065151	A1	20030403	US 2002-115123	20020404 <--
PRAI	US 1998-89507P	P	19980616 <--		
	US 1998-89508P	P	19980616 <--		
	US 1998-89509P	P	19980616 <--		

US 1998-89510P P 19980616 <--
US 1998-90112P P 19980622 <--
US 1998-90113P P 19980622 <--
WO 1999-US13418 A2 19990615 <--
US 1999-461325 A3 19991214 <--

AB The present invention relates to 94 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins (Sequences for Seq ID:1-252 are not provided, in which only Seq ID 161 is claimed). Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

IT **252322-58-0**
RL: PRP (Properties)
(unclaimed sequence; cloning and cDNA and deduced amino acid sequences of 94 human secreted proteins)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon	1995				
Anon	1995				
Anon	1997				
Anon	1997				
Anon	1997				
Anon	1997				
Anon	1997				
Anon	1997				
Anon	1999				
Anon	1999				
Anon	1999			WO 9966041	HCAPLUS
Anon	2000				
Anon	2000				
Anon	2000				
Anon	2000				
Anon	2000				
Anon	2000				
Anon	2000				
Anon	2001				
Anon	2001				
Anon	2001			WO 0151520	HCAPLUS
Brittis	2001	30	11	Neuron	HCAPLUS
Fournier	2001	409	341	Nature	HCAPLUS
Goldberg	2000	403	369	Nature	HCAPLUS
Grandpre	2000	403	439	Nature	HCAPLUS
Grandpre, T	2002	417		Nature	HCAPLUS
Groner	1996			US 5534409 A	HCAPLUS
Jacobs	1997	198	289	Gene	HCAPLUS
Ng	2002	67	559	Journal of Neuroscie	HCAPLUS
Schwab	1993			US 5250414 A	HCAPLUS
Schwab	1997			US 5684133 A	HCAPLUS
Schwab	2000			US 6103232 A	HCAPLUS

L31 ANSWER 23 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:755062 HCAPLUS
DN 137:274034
TI Methods for the early diagnosis of ovarian cancer by screening for stratum corneum chymotryptic enzyme (SCCE) mRNA in tissue and its treatment

IN O'Brien, Timothy J.; Cannon, Martin J.; Santin, Alessandro
PA The Board of Trustees of the University of Arkansas, USA
SO U.S. Pat. Appl. Publ., 60 pp., Cont.-in-part of U.S. Ser. No. 905,083.
CODEN: USXXCO
DT **Patent**
LA English
FAN.CNT 12

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	US 2002142317	A1	20021003		US 2001-918243	20010730	<--
	US 6627403	B2	20030930				
	US 6303318	B1	20011016		US 1998-39211	19980314	<--
	US 6294344	B1	20010925		US 2000-502600	20000211	<--
	US 2002146708	A1	20021010		US 2001-905083	20010713	<--
	US 2003223973	A1	20031204		US 2003-372521	20030221	<--
PRAI	US 1997-41404P	P	19970319	<--			
	US 1998-39211	A2	19980314	<--			
	US 2000-502600	A3	20000211				
	US 2001-905083	A2	20010713				
	US 2001-918243	A2	20010730				

AB This invention allows for the detection of cancer, especially ovarian cancer, by screening for stratum corneum chymotryptic enzyme (SCCE) mRNA in tissue. The invention provides methods of inhibiting expression of stratum corneum chymotryptic enzyme in a cell by SSCE antisense mRNA or antibody specific for stratum corneum chymotryptic enzyme protein or a fragment thereof. In another embodiment the present invention provides method of vaccinating an individual against SCCE or produce immune-activated cells directed toward SSCE by inoculating an individual with a SSCE protein or a fragment thereof that lacks SSCE protease activity. The disclosed nucleic acid primer sets, used in combination with quant. amplification (PCR) of tissue cDNA, can indicate the presence of specific proteases in a tissue sample. The detected proteases are themselves specifically overexpressed in certain cancers, and their presence may serve for early detection of associated ovarian and other malignancies, and for the design of interactive therapies for cancer treatment. More specifically, the present invention relates to the uses of stratum corneum chymotrytic enzyme as a marker for ovarian tumor cells.
IT **355838-88-9 355839-03-1 355839-23-5**
RL: PRP (Properties)
(unclaimed sequence; methods for the early diagnosis of ovarian cancer by screening for stratum corneum chymotryptic enzyme (SCCE) mRNA in tissue and its treatment)

L31 ANSWER 24 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:658587 HCAPLUS
DN 137:195557
TI Ovarian tumor associated proteins and cDNAs and compositions and methods for therapy and diagnosis of ovarian cancer
IN Algate, Paul A.; Carter, Darrick
PA Corixa Corporation, USA
SO U.S. Pat. Appl. Publ., 317 pp., Cont.-in-part of U.S. Ser. No. 827,271.
CODEN: USXXCO
DT **Patent**
LA English
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 2002119158	A1	20020829	US 2001-884441	20010618	<--
	US 6528253	B1	20030304	US 1998-215681	19981217	<--
	US 6670463	B1	20031230	US 1998-216003	19981217	<--
	US 6488931	B1	20021203	US 1999-338933	19990623	<--
	US 6468546	B1	20021022	US 1999-404879	19990924	<--

	US 6699664	B1	20040302	US 2000-667857	20000920 <--
	US 2003165504	A1	20030904	US 2001-827271	20010404 <--
	ZA 2001004510	A	20021125	ZA 2001-4510	20010531 <--
	WO 2002006317	A2	20020124	WO 2001-US22635	20010717
	WO 2002006317	A3	20030703		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	US 2003091580	A1	20030515	US 2001-907969	20010717 <--
	EP 1349870	A2	20031008	EP 2001-954748	20010717

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

	US 2003124140	A1	20030703	US 2002-198053	20020717 <--
	NO 2003000211	A	20030314	NO 2003-211	20030116
PRAI	US 1998-215681	A2	19981217 <--		
	US 1998-216003	A2	19981217 <--		
	US 1999-338933	A2	19990623 <--		
	US 1999-404879	A2	19990924 <--		
	US 2000-617747	A2	20000717		
	US 2000-636801	A2	20000810		
	US 2000-667857	A2	20000920		
	US 2000-667857	A2	20000920		
	US 2001-827271	A2	20010404		
	US 2001-884441	A	20010618		
	US 2001-907969	A2	20010717		
	WO 2001-US22635	W	20010717		

AB The invention provides protein and cDNA sequences of a novel human protein 0772P, which is over-expressed in ovarian small cell carcinoma by microarray, immunohistochem. and PCR subtraction anal. Compns. and methods for the therapy and diagnosis of cancer, such as ovarian cancer, are disclosed. Compns. may comprise one or more ovarian tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a ovarian tumor protein, or a T cell that is specific for cells expressing such a protein. Such compns. may be used, for example, for the prevention and treatment of diseases such as ovarian cancer. Diagnostic methods based on detecting a ovarian tumor protein, or mRNA encoding such a protein, in a sample are also provided.

IT **389603-31-0 389603-49-0 389603-50-3**
RL: PRP (Properties)
(unclaimed sequence; ovarian tumor associated proteins and cDNAs and compns. and methods for therapy and diagnosis of ovarian cancer)

L31 ANSWER 25 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:488149 HCAPLUS
DN 137:58667
TI Differentially expressed sequences and proteins for use in therapy and diagnosis of human prostate cancer
IN Xu, Jiangchun; Dillon, Davin C.; Mitcham, Jennifer L.; Harlocker, Susan L.; Jiang, Yuqiu; Kalos, Michael D.; Fanger, Gary R.; Retter, Marc W.; Stolk, John A.; Day, Craig H.; Vedvick, Thomas S.; Carter, Darrick; Li, Samuel X.; Wang, Aijun; Skeiky, Yasir A. W.; Hepler, William T.; Henderson, Robert A.; Hural, John; McNeill, Patricia D.; Houghton, Raymond L.; De Bassols, Carlota Vinals
PA USA
SO U.S. Pat. Appl. Publ., 87 pp., Cont.-in-part of U.S. Ser. No. 780,669.
CODEN: USXXCO

DT **Patent**
LA English
FAN.CNT 28

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	US 2002081680	A1	20020627		US 2001-822827	20010328	<--
	US 2002051977	A1	20020502		US 2001-780669	20010209	<--
	US 2002192763	A1	20021219		US 2001-895793	20010629	<--
PRAI	US 1999-157455P	P	19991004	<--			
	US 2000-679272	A2	20001004				
	US 2001-780669	A2	20010209				
	US 1997-806099	B2	19970225	<--			
	US 1997-904804	B2	19970801	<--			
	US 1998-20956	A2	19980209	<--			
	US 1998-30607	A2	19980225	<--			
	WO 1998-US3492	A2	19980225	<--			
	US 1998-115453	A2	19980714	<--			
	US 1998-159812	A2	19980923	<--			
	US 1999-232149	A2	19990115	<--			
	US 1999-288946	A2	19990409	<--			
	US 1999-352616	A2	19990713	<--			
	WO 1999-US15838	A2	19990714	<--			
	US 1999-439313	A2	19991112	<--			
	US 1999-443686	B2	19991118	<--			
	US 2000-483672	A2	20000114				
	US 2000-536857	A2	20000327				
	US 2000-157455P	P	20000417				
	US 2000-510737	A2	20000501				
	US 2000-568100	A2	20000509				
	US 2000-593793	A2	20000613				
	US 2000-605783	A2	20000627				
	US 2000-636215	A2	20000810				
	US 2000-651236	A2	20000829				
	US 2000-657279	A2	20000906				
	US 2000-679426	A2	20001002				
	US 2000-685166	A2	20001010				
	US 2000-709729	A2	20001109				
	US 2001-759143	A2	20010112				
	US 2001-822827	A2	20010328				

AB Prostate-specific expressed genes (cDNA) and their encoded proteins useful for the therapy and diagnosis of cancer, particularly prostate cancer, are identified by conventional and PCR-based hybridization subtraction, electronic subtraction, and microarray anal. of cDNAs from a human prostate tumor cDNA library. Illustrative compns. comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen-presenting cells that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compns. are useful, for example, in the diagnosis prevention and/or treatment of diseases, particularly prostate cancer.

IT **350473-94-8 350473-96-0**
RL: PRP (Properties)
(unclaimed sequence; differentially expressed sequences and proteins for use in therapy and diagnosis of human prostate cancer)

L31 ANSWER 26 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:332612 HCAPLUS
DN 136:351438
TI Nucleic acid and protein compositions and methods for the therapy and diagnosis of prostate cancer
IN Xu, Jiangchun; Dillon, Davin C.; Mitcham, Jennifer L.; Harlocker, Susan L.; Jiang, Yuqiu; Kalos, Michael D.; Fanger, Gary R.; Retter, Marc W.; Stolk, John A.; Day, Craig H.; Vedvick, Thomas S.; Carter, Darrick; Li,

Samuel X.; Wang, Aijun; Skeiky, Yasir A. W.; Hepler, William T.; Henderson, Robert A.; Hural, John; McNeill, Patricia D.; Houghton, Raymond L.

PA USA

SO U.S. Pat. Appl. Publ., 89 pp., Cont.-in-part of U.S. Ser. No. 759,143.
CODEN: USXXCO

DT **Patent**

LA English

FAN.CNT 28

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 2002051977	A1	20020502	US 2001-780669	20010209	<--
	US 6261562	B1	20010717	US 1998-20956	19980209	<--
	WO 9837093	A2	19980827	WO 1998-US3492	19980225	<--
	WO 9837093	A3	19981217			
	W: AL, AM, AT, AU, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
	ZA 9801585	A	19980904	ZA 1998-1585	19980225	<--
	US 6262245	B1	20010717	US 1998-30607	19980225	<--
	US 2002090372	A1	20020711	US 1998-115453	19980714	<--
	US 6657056	B2	20031202			
	US 6613872	B1	20030902	US 1998-159812	19980923	<--
	US 6465611	B1	20021015	US 1999-232149	19990115	<--
	US 6395278	B1	20020528	US 1999-352616	19990713	<--
	WO 2000004149	A2	20000127	WO 1999-US15838	19990714	<--
	WO 2000004149	A3	20000720			
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
	US 6329505	B1	20011211	US 1999-439313	19991112	<--
	US 6512094	B1	20030128	US 2000-593793	20000613	<--
	US 6620922	B1	20030916	US 2000-636215	20000810	<--
	US 6630305	B1	20031007	US 2000-685166	20001010	<--
	US 2002022248	A1	20020221	US 2001-759143	20010112	<--
	US 2002081680	A1	20020627	US 2001-822827	20010328	<--
	US 2002193296	A1	20021219	US 2001-895814	20010629	<--
	US 2002183251	A1	20021205	US 2001-12896	20011210	<--
	US 2003157089	A1	20030821	US 2002-144678	20020509	<--
	US 2003185830	A1	20031002	US 2002-294025	20021112	<--
PRAI	US 1997-806099	B2	19970225	<--		
	US 1997-904804	B2	19970801	<--		
	US 1998-20956	A2	19980209	<--		
	US 1998-30607	A2	19980225	<--		
	WO 1998-US3492	A2	19980225	<--		
	US 1998-115453	A2	19980714	<--		
	US 1998-159812	A2	19980923	<--		
	US 1999-232149	A2	19990115	<--		
	US 1999-288946	A2	19990409	<--		
	US 1999-352616	A2	19990713	<--		
	WO 1999-US15838	A2	19990714	<--		
	US 1999-439313	A2	19991112	<--		

US 1999-443686	B2	19991118	<--
US 2000-483672	A2	20000114	
US 2000-536857	A2	20000327	
US 2000-510737	A2	20000501	
US 2000-568100	A2	20000509	
US 2000-593793	A2	20000613	
US 2000-605783	A2	20000627	
US 2000-636215	A2	20000810	
US 2000-651236	A2	20000829	
US 2000-657279	A2	20000906	
US 2000-679426	A2	20001002	
US 2000-685166	A2	20001010	
US 2000-709729	A2	20001109	
US 2001-759143	A2	20010112	
US 1998-116134	A	19980717	<--
US 1998-159822	A	19980923	<--
US 1999-232880	A	19990115	<--
US 1999-157455P	P	19991004	<--
US 2000-570737	A2	20000512	
US 2000-679272	A2	20001004	
US 2001-780669	A2	20010209	
US 2001-852911	A2	20010509	
US 2001-895814	A2	20010629	
US 2001-12896	A2	20011210	
US 2002-144678	A2	20020509	

AB Compns. and methods for the therapy and diagnosis of cancer, particularly prostate cancer, are disclosed. Thus, nucleic acids encoding prostate tumor-specific antigens were isolated from human prostate cDNA libraries by differential display, PCR-based subtraction, microarray anal., and electronic subtraction. Illustrative compns. comprise one or more prostate-specific polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen-presenting cells that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compns. are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly prostate cancer.

IT **350473-94-8P 350473-96-0P**
RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(epitope from protein P501S; nucleic acid and protein compns. and methods for the therapy and diagnosis of prostate cancer)

L31 ANSWER 27 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:52003 HCAPLUS
DN 136:117371
TI Method of inducing an immunological CTL response by lymphatic system delivery of peptide vaccine
IN Kundig, Thomas M.; Simard, John J. L.
PA Switz.
SO U.S. Pat. Appl. Publ., 48 pp., Cont.-in-part of U. S. Ser. No. 380,534.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 7

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2002007173	A1	20020117	US 2001-776232	20010202 <--
WO 9902183	A2	19990121	WO 1998-US14289	19980710 <--
WO 9902183	A3	19990514		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,

NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	AU 2001097432	A5	20020808	AU 2001-97432	20011221
	WO 2002062368	A2	20020815	WO 2002-US2033	20020122
	WO 2002062368	A3	20030925		
	WO 2002062368	C1	20031120		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	US 2003138808	A1	20030724	US 2002-225568	20020820 <--
PRAI	CA 1997-2209815	A	19970710 <--		
	US 1997-988320	B2	19971210 <--		
	WO 1998-US14289	W	19980710 <--		
	US 1999-380534	A2	19990901 <--		
	US 1998-26066	A2	19980219 <--		
	US 2000-561572	A2	20000428		
	US 2000-715835	A2	20001116		
	US 2001-776232	A	20010202		
	US 2001-336968P	P	20011107		
	US 2001-337017P	P	20011107		
	US 2002-363210P	P	20020307		
	US 2002-117937	A2	20020404		

AB Disclosed herein are methods for inducing an immunol. CTL response to an antigen by sustained, regular delivery of the antigen to a mammal so that the antigen reaches the lymphatic system. Antigen is delivered at a level sufficient to induce an immunol. CTL response in a mammal and the level of the antigen in the mammal's lymphatic system is maintained over time sufficient to maintain the immunol. CTL response. Also disclosed is an article of manufacture for delivering an antigen that induces a CTL response in an animal. The antigen can be used in vaccines for cancer or infection.

IT **390884-75-0**
RL: PRP (Properties)
(unclaimed sequence; method of inducing an immunol. CTL response by lymphatic system delivery of peptide vaccine)

L31 ANSWER 28 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:916418 HCAPLUS
DN 136:48813
TI Method for treating AIDS and HIV infection using select peptides from the beta subunit of human chorionic gonadotropin
IN Bourinbaiar, Aldar S.
PA Metatron, Inc., USA
SO U.S., 21 pp.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6331610	B1	20011218	US 1997-908371	19970807 <--
PRAI US 1997-44937P	P	19970425 <--		

AB The present invention relates to select peptides of the C-terminal and amino-terminal portion of the beta unit of hCG and pharmaceutically acceptable derivs. thereof that can be used for controlling retroviral,

e.g., human immunodeficiency virus (BV infections). The invention comprises a method in vitro as well as in vivo for prevention and/or treatment of acquired immune deficiency syndrome (AIDS) at pharmacol. doses of beta hCG-derived peptides and pharmaceutically acceptable derivs. thereof which are sufficient to exert an anti-HIV effect for a sufficient period of time. Claimed is a method for inhibiting the spread of HIV infection in a fetus of an HIV-infected mother comprising administering beta hCG-derived peptides and/or their derivs. to said mother of said fetus. Administration of beta hCG-derived peptides and/or their derivs. in combination with other treatment agents is also claimed.

IT **116088-06-3**
RL: BSU (Biological study, unclassified); **PAC (Pharmacological activity)**; PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(amino acid sequence; method for treating AIDS and HIV infection using select peptides and peptide derivs. from beta subunit of human chorionic gonadotropin)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Bergamini	1992	40		J Virol Methods	HCAPLUS
Birken, S	1984	45		Ann Endocrinol	HCAPLUS
Bourinbaiar	1992	309	82	FEBS	HCAPLUS
Bourinbaiar	1992	96	27	FEMS Microbiology Le	HCAPLUS
Bourinbaiar	1995	44	13	Immunology Letters	HCAPLUS
Bourinbaiar	1997	61	PL149	Life Sciences	HCAPLUS
Bourinbaiar, A	1997	61	149	Pharm Letters	
Carlsen	1973	248	6810	The Journal of Biolo	HCAPLUS
Carlsen, R	1973	248	6810	J Bio Chem	HCAPLUS
Droge	1997			US 5607974	HCAPLUS
Drossigk	1996	109		Berl Munch Tierarztl	MEDLINE
Gallo	1998	16	218	Nature Biotechnology	HCAPLUS
Gallo, R	1998	16	218	Nature Biotechnology	HCAPLUS
Gustafson	1989	81		J Natl Cancer Inst	HCAPLUS
Harris	1997			US 5700781	HCAPLUS
Hotoda	1993	29		Nucleic Acids Symp S	HCAPLUS
Jellinger	1997	175		J Infect Dis	HCAPLUS
Jones	1988	1		Lancet	MEDLINE
Kalvatchev	1997	51		Biomed Pharmacother	MEDLINE
Kaneda	1995	15		Invasion Metstasis	HCAPLUS
Kira	1995	11		AIDS Res Hum Retrovi	HCAPLUS
Kochanowska	1995	43		Arch Immunol Ther Ex	HCAPLUS
Longhi	1986	92		J Immunol Methods	HCAPLUS
Lunardi-Iskandar	1997			US 5677275	HCAPLUS
Makovsky	1996	58		J Virol Methods	
Nakashima	1988	26		J Virol Methods	MEDLINE
Ohio State University	1996	35		Am J Reprod Immunol	
Pauwels	1988	20		J Virol Methods	HCAPLUS
Robertson	1988	20		J Virol Methods	
Shimizu	1993	16		Biol Pharm Bull	HCAPLUS
Stevens	1981			US 4302386	HCAPLUS
Stevens	1983			US 4384995	HCAPLUS
Stevens	1985			US 4526716	HCAPLUS
Wehmann	1981	68		J Clin Invest	HCAPLUS
Wehmann	1983	71		J Clin Invest	
Weislow	1989	81		J Natl Cancer Inst	
Witvrouw	1998	11		AIDS Res Hum Retrovi	

L31 ANSWER 29 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:895574 HCAPLUS
DN 136:52707
TI Methods for the treatment of immunologically-mediated skin disorders

IN Watson, James D.; Tan, Paul L. J.; Prestidge, Ross
PA Genesis Research & Development Corp. Ltd., N. Z.
SO U.S., 116 pp., Cont.-in-part of U.S. 5,968,524.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6328978	B1	20011211	US 1999-324542	19990602 <--
	US 5968524	A	19991019	US 1997-997080	19971223 <--
	US 2003007976	A1	20030109	US 2001-880505	20010613 <--
PRAI	US 1997-997080	A2	19971223 <--		
	US 1999-324542	A2	19990602 <--		

AB Methods for the treatment of skin disorders, including psoriasis, atopic dermatitis, allergic contact dermatitis, alopecia areata and skin cancers are provided, such methods comprising administering a composition having antigenic and/or adjuvant properties. Compns. which may be usefully employed in the inventive methods include inactivated M. vaccae cells, delipidated and deglycolipidated M. vaccae cells, M. vaccae culture filtrate and compds. present in or derived therefrom, together with combinations of such compns.

IT **380685-44-9**
RL: BSU (Biological study, unclassified); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(inactivated or delipidated and deglycolipidated Mycobacterium vaccae or antigens for treatment of immunol.-mediated skin disorders)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Adam	1977			US 4036953	HCAPLUS
Anon	1990			WO 9007935	HCAPLUS
Anon	1991			WO 9101751	
Anon	1991			WO 9102542	HCAPLUS
Anon	1992			WO 9208484	
Anon	1992			WO 9208488	
Anon	1993			EP 0556248 B1	
Anon	1993			WO 9316727	
Anon	1994			WO 9406466	HCAPLUS
Anon	1995			WO 9526742	
Anon	1991		21	Evan Medical Marketl	
Jolles	1976			US 3956481	HCAPLUS
Lehrer, A	1998	21	71	FEMS Immunology and	HCAPLUS
Ramu	1990	124	381	Indian J Med Gazette	
Rook	1988			US 4724144	
Stanford	1987			US 4716038	HCAPLUS
Stanford	1997			US 5599545	
Stanford	1998			US 5833996	HCAPLUS
Tan	1999			US 5985287	HCAPLUS
Tan	1999			US 6001361	HCAPLUS
Watson	1999			US 5968524	HCAPLUS
White, R	1958	I	54	Immunology	
White, R	1964	7	158	Immunology	
White, R	1967	6	49	Symposium Series Imm	

L31 ANSWER 30 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:703797 HCAPLUS
DN 135:269289
TI Human transmembrane serine protease TADG-12 overexpressed in ovarian carcinoma and diagnosis treatment and prophylaxis of ovarian cancer
IN O'Brien, Timothy J.; Underwood, Lowell J.
PA The Board of Trustees of the University of Arkansas, USA

SO U.S., 63 pp., Cont.-in-part of U.S. Ser. No. 261,416.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 6294663	B1	20010925	US 2000-518046	20000302	<--
	US 6291663	B1	20010918	US 1999-261416	19990303	<--
	US 2003170707	A1	20030911	US 2003-357175	20030203	<--
	US 2003207316	A1	20031106	US 2003-455720	20030605	<--
PRAI	US 1999-261416	A2	19990303	<--		
	US 2000-518046	A3	20000302			
	US 2000-650371	A2	20000828			

AB The present invention provides a Tumor Aoosociated Differentially Expressed Gene (TADG-12) encoding a serine proteinase that is found at high levels in ovarian cancers. Also provided is a vector/host cell capable of expressing the DNA. The present invention further provides various methods of early detection of associated ovarian and other malignancies, and of interactive therapies for cancer treatment by utilizing the DNA and/or protein disclosed herein. The mRNA and a number of splice variants are found at elevated levels in cancerous ovarian tissues but are absent or at low levels in normal ovary. Sequences for two isoenzymes arising from differential splicing are claimed. Epitopes of the protein are reported.
IT **290813-57-9 290813-83-1 290814-24-3**
RL: PRP (Properties)
(unclaimed sequence; human transmembrane serine protease TADG-12 overexpressed in ovarian carcinoma and diagnosis treatment and prophylaxis of ovarian cancer)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon	1998			WO 9841656	HCAPLUS
Koivunen	1990	50	2375	Cancer Research	MEDLINE
O'Brien	1998	19	33	Tumor Biology	
Tanimoto	1998	39	648	Proceedings of the A	

L31 ANSWER 31 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:64014 HCAPLUS
DN 134:110451
TI Peptides and their utility in modulation of behavior of cells expressing . **alpha.3.beta.1 integrins**
IN **Roberts, David D.; Krutzsch, Henry C.**
PA United States Dept. of Health and Human Services, USA
SO PCT Int. Appl., 84 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2001005812	A2	20010125	WO 2000-US18986	20000712	<--
	WO 2001005812	A3	20010503			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,

CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 2000060902 A5 20010205 AU 2000-60902 20000712 <--
PRAI US 1999-144549P P 19990715 <--
WO 2000-US18986 W 20000712
OS MARPAT 134:110451
AB The present invention relates to a peptide comprising the sequence R1-X1-X2-X3-X4-R2, wherein X1 is selected from the group consisting of N, Q, D and S; X2 is selected from the group consisting of V, I and L; X3 is selected from the group consisting of R and K; and X4 is selected from the group consisting of V, I, L and F; R1 is a hydrogen or a peptide of 1 to 6 amino acids, an acyl or an aryl group; and R2 is a peptide of 1 to 3 amino acids, a hydroxide or an amide. The invention also relates to partial or full retro-inverso peptides comprising the above sequences. The invention also relates to peptide-substrate combination comprising a substrate suitable for cell growth and the peptide of the invention, and to a vascular graft and an artificial blood vessel comprising the peptide-substrate combination. The invention also relates to a pharmaceutical composition and a peptide conjugate comprising the peptide of the invention. The invention also relates to a method of inhibiting adhesion of a cell expressing **.alpha.3β 1 integrin** to an extracellular matrix, inhibiting **alpha.3.beta.1-integrin** -mediated cell motility, inhibiting **.alpha.3. beta.1-integrin** mediated cell proliferation, promoting **.alpha.3.beta.1- integrin** mediated cell proliferation and inhibiting angiogenesis utilizing the peptides of the invention.
IT **247111-59-7 247111-61-1 247111-63-3 247111-64-4 247111-65-5 247111-66-6 247111-67-7 247111-68-8 247111-70-2 247111-74-6 247111-78-0 321522-53-6 321522-54-7 321522-55-8 321522-56-9 321522-59-2 321522-60-5 321522-61-6**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptides for modulation of behavior of cells expressing α **3β 1 integrins**)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Adachi, M	1998	16	1060	J Clin Oncol	HCAPLUS
Adams, J	1995	108	1977	J Cell Sci	HCAPLUS
Akiyama, S	1985	260	4492	J Biol Chem	HCAPLUS
Akiyama, S	1985	260	4492	J Biol Chem	HCAPLUS
Almquist, R	1980	23	1392	J Med Chem	HCAPLUS
Anon				Remington's Pharmace	
Aota, S	1995	70	1	Adv Enzymol Relat Ar	HCAPLUS
Atherton	1989			Solid Phase Peptide	
Bagavandoss, P	1990	170	867	Biochem Biophys Res	HCAPLUS
Beckmann, G	1998	275	725	J Mol Biol	HCAPLUS
Benezra, D	1993	34	3601	Invest Ophthalmol Vi	MEDLINE
Bornstein, P	1992	6	3290	FASEB J	HCAPLUS
Bornstein, P	1995	130	503	J Cell Biol	HCAPLUS
Brooks, P	1995	96	1815	J Clin Invest	HCAPLUS
Brooks, P	1994	264	569	Science	HCAPLUS
Brunswick	1988	140	3364	J Immunol	HCAPLUS
Canfield, A	1990	268	225	Biochem J	HCAPLUS
Canfield, A	1995	108	797	J Cell Sci	HCAPLUS
Chandrasekaran, S	1999	274	11408	J Biol Chem	HCAPLUS
Chen, Z	1996	106	215	J Invest Dermatol	HCAPLUS

Chorev, M	1993	26	266	Acc Chem Res	HCAPLUS
Clezardin, P	1997	321	819	Biochem J	HCAPLUS
Crawford, S	1998	93	1159	Cell	HCAPLUS
Dameron, K	1994	265	1582	Science	HCAPLUS
Dawson, D	1997	138	707	J Cell Biol	HCAPLUS
Defreitas, M	1995	15	333	Neuron	HCAPLUS
Delwel, G	1994	5	203	Mol Biol Cell	HCAPLUS
Eble, J	1998	37	10945	Biochemistry	HCAPLUS
Elices, M	1991	112	169	J Cell Biol	HCAPLUS
Emsley, J	1994	367	338	Nature	HCAPLUS
Evans	1987	30	1229	J Med Chem	HCAPLUS
Fauchere, J	1986	15	29	Adv Drug Res	HCAPLUS
Fenczik, C	1997	390	81	Nature	HCAPLUS
Fermandez, C	1998	3	684	Frontiers Biosci	
Folkman, J	1995	1	27	Nat Med	HCAPLUS
Gao, A	1996	271	21	J Biol Chem	HCAPLUS
Gao, A	1996	135	533	J Cell Biol	HCAPLUS
Gehlsen, K	1992	117	449	J Cell Biol	HCAPLUS
Gilman	1990			Goodman and Gilman's	
Godyna, S	1995	129	1403	J Cell Biol	HCAPLUS
Gonzales, M	1999	10	259	Mol Biol Cell	HCAPLUS
Good, D	1990	87	6624	Proc Natl Acad Sci U	HCAPLUS
Goodman, M	1979	12	1	Acc Chem Res	HCAPLUS
Greisler, H	1991			New Biologic and Syn	
Gresham, H	1996	271	30587	J Biol Chem	HCAPLUS
Guo, N	1997	57	1735	Cancer Res	HCAPLUS
Guo, N	1998	58	3154	Cancer Res	HCAPLUS
Guo, N	1992	267	19349	J Biol Chem	HCAPLUS
Guo, N	1997	50	210	J Peptide Res	HCAPLUS
Guo, N	1992	89	3040	Proc Natl Acad Sci U	HCAPLUS
Gupta, K	1999	1453	63	Biochim Biophys Acta	HCAPLUS
Hanahan, D	1996	86	353	Cell	HCAPLUS
Hann, M	1982		307	J Chem Soc Perkin Tr	HCAPLUS
Hemler, M	1990	32	229	Cell Differ Dev	HCAPLUS
Hemler, M	1984	132	3011	J Immunol	HCAPLUS
Holladay, M	1983	24	4401	Tetrahedron Lett	HCAPLUS
Hruby, V	1982	31	189	Life Sci	HCAPLUS
Hsu, S	1996	56	5684	Cancer Res	HCAPLUS
Hudson, D	1979	14	177	Int J Pept Prot Res	HCAPLUS
Inman, J	1975	114	704	J Immunol	HCAPLUS
Iruela, A	1991	88	5026	Proc Natl Acad Sci U	
Iruela-Arispe	1999			Circulation in press	
Jennings-White, C	1982	23	2533	Tetrahedron Lett	HCAPLUS
Joyce, N	1989	30	1548	Invest Ophthalmol Vi	MEDLINE
Keenan, R	1997	40	2289	J Med Chem	HCAPLUS
Koyama, H	1996	87	1069	Cell	HCAPLUS
Kreidberg, J	1996	122	3537	Development	HCAPLUS
Krukonis, E	1998	273	31837	J Biol Chem	HCAPLUS
Krutzsch, H	1999	274	24080	J Biol Chem	HCAPLUS
Lahav, J	1988	177	199	Exp Cell Res	HCAPLUS
Lawler, J	1988	107	2351	J Cell Biol	HCAPLUS
Lawrence, C	1993	262	208	Science	HCAPLUS
Legrand, C	1992	79	1995	Blood	HCAPLUS
Mainiero, F	1997	16	2365	Embo J	HCAPLUS
Merck & Co				MERCK INDEX	
Merrifield	1963	85	2149	J Amer Chem Soc	HCAPLUS
Merrifield	1986	232	341	Science	HCAPLUS
Miles, A	1995	270	29047	J Biol Chem	HCAPLUS
Mongini, P	1992	148	3892	J Immunol	HCAPLUS
Morandi, V	1993	29A	585	In Vitro Cell Dev Bi	HCAPLUS
Morelli, D	1998	4	1221	Clin Cancer Res	MEDLINE
Morley, J	1980		463	Trends Pharm Sci	HCAPLUS
Mumby, S	1984	120	280	J Cell Physiol	HCAPLUS

Munjal, I	1990	52	252	Eur J Cell Biol	HCAPLUS
Murphy-Ullrich, J	1993	268	26784	J Biol Chem	HCAPLUS
Murphy-Ullrich, J	1989	109	1309	J Cell Biol	HCAPLUS
Nicosia, R	1994	124	183	J Cell Biol	HCAPLUS
Norris	1989			Novel Drug Delivery	
Panetti, T	1997	129	208	J Lab Clin Med	HCAPLUS
Passaniti, A	1992	67	519	Lab Invest	MEDLINE
Polverini, P	1995	6	230	Crit Rev Oral Biol M	MEDLINE
Prater, C	1991	112	1031	J Cell Biol	HCAPLUS
Reed, M	1995	147	1068	American Journal of	HCAPLUS
Roberts, A	1986	83	4167	Proc Natl Acad Sci U	HCAPLUS
Roberts, D	1996	10	1183	FASEB J	HCAPLUS
Roberts, D	1994	16	217	J Tissue Cult Method	
Roche	1987			Bioreversible Carrie	
Ruoslahti, E	1996	12	697	Ann Rev Cell Dev Bio	HCAPLUS
Sambrook	1989	1-3		Molecular Cloning:A	
Schuler, G	1991	9	180	Prot Struct Funct Ge	HCAPLUS
Schultz-Cherry, S	1993	122	923	J Cell Biol	HCAPLUS
Sechler, J	1998	273	25533	J Biol Chem	HCAPLUS
Sheibani, N	1995	92	6788	Proc Natl Acad Sci U	HCAPLUS
Shrive, A	1996	3	346	Nature Struct Biol	HCAPLUS
Sipes, J	1999			J Biol Chem in press	
Spatola, A	1983		267	Chemistry and Bioche	HCAPLUS
Spatola, A	1986	38	1243	Life Sci	HCAPLUS
Spatola, A	1983	1		Vega Data	
Stahl, S	1997	110	55	J Cell Sci	HCAPLUS
Suzuma, K	1999	154	343	Am J Pathol	HCAPLUS
Swerlick, R	1992	148	78	J Immunol	HCAPLUS
Szelke, M	1982			EP 45665	HCAPLUS
Taraboletti, G	1990	111	765	J Cell Biol	HCAPLUS
Tolsma, S	1993	122	497	J Cell Biol	HCAPLUS
Tolsma, S	1997	54	13	Microvasc Res	HCAPLUS
Veber	1985		392	TINS	HCAPLUS
Vischer, P	1988	47	36	Eur J Cell Biol	HCAPLUS
Vischer, P	1997	73	332	Eur J Cell Biol	HCAPLUS
Vogel, T	1993	53	74	J Cell Biochem	HCAPLUS
Volpert, O	1995	217	326	Biochem Biophys Res	HCAPLUS
Volpert, O	1998	95	6343	Proc Natl Acad Sci U	HCAPLUS
Weinstat-Saslow, D	1994	54	6504	Cancer Res	HCAPLUS
Weitzman, J	1996	4	41	Cell Adhes Commun	HCAPLUS
Weitzman, J	1993	268	8651	J Biol Chem	HCAPLUS
Wu, C	1995	108	2511	J Cell Sci	HCAPLUS
Yabkowitz, R	1993	151	149	J Immunol	HCAPLUS
Yamada, K	1991	266	12809	J Biol Chem	HCAPLUS
Yanez-Mo, M	1998	141	791	J Cell Biol	HCAPLUS
Yokosaki, Y	1996	271	24144	J Biol Chem	HCAPLUS

L31 ANSWER 32 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:891461 HCAPLUS
DN 134:51386
TI Cytomodulating peptides for inhibiting lymphocyte activity
IN Buelow, Roland
PA Sangstat Medical Corp., USA
SO U.S., 20 pp.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6162434	A	20001219	US 1995-433613	19950503 <--
PRAI US 1995-433613		19950503 <--		

OS MARPAT 134:51386

AB Oligopeptides comprising a sequence associated with HLA-B α1 domain, but comprising a tyrosine-tyrosine-tryptophan triad, are provided for use in inhibiting cytotoxic activity of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells. By combining the compns. of the invention with mixts. of cells comprising the cytotoxic cells and cells which would otherwise activate the cytotoxic cells, lysis of the target cells can be substantially inhibited. The oligopeptides may be joined to a wide variety of other groups or compds. for varying the activity of the compns. The compns. may be administered by any convenient means to a host to inhibit CTL and NK cell attack on tissue, particularly involved with xenogeneic or allogeneic transplants.

IT **213177-52-7 313055-40-2 313055-41-3**
313547-45-4 313547-46-5 313547-47-6
RL: PRP (Properties)
(unclaimed sequence; cytomodulating peptides for inhibiting lymphocyte activity)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon	1988			WO 8805784	HCAPLUS
Anon	1993			WO 9308817	HCAPLUS
Anon	1993			WO 9317699	HCAPLUS
Anon	1994			WO 9402162	HCAPLUS
Anon	1995			WO 9513288	HCAPLUS
Bjorkman, P	2000	329	506	Nature	
Buelow	1995	59	649	Transplantation	HCAPLUS
Dal Porto, J	1993	90	6671	Proc Natl Acad Sci U	HCAPLUS
Wood, W	1981		14	Biochemistry	

L31 ANSWER 33 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:291095 HCAPLUS
DN 132:329919
TI Modified peptides containing an antibody Fc domain as therapeutic agents
IN Feige, Ulrich; Liu, Chuan-fa; Cheetham, Janet; Boone, Thomas Charles
PA Amgen Inc., USA
SO PCT Int. Appl., 608 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2000024782	A2	20000504	WO 1999-US25044	19991025	<--
	WO 2000024782	A3	20020606			
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
	US 6660843	B1	20031209	US 1999-428082	19991022	<--
	EP 1144454	A2	20011017	EP 1999-971003	19991025	<--
	EP 1144454	A3	20020911			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
	BR 9914708	A	20020716	BR 1999-14708	19991025	<--
	JP 2003512011	T2	20030402	JP 2000-578351	19991025	<--
	AU 767725	B2	20031120	AU 2000-12322	19991025	<--
	ZA 2001002753	A	20020611	ZA 2001-2753	20010404	<--

	NO 2001001963	A	20010621	NO 2001-1963	20010420	<--
	BG 105461	A	20030430	BG 2001-105461	20010424	<--
	US 2004044188	A1	20040304	US 2003-609217	20030627	<--
	US 2004053845	A1	20040318	US 2003-632388	20030731	<--
	US 2004057953	A1	20040325	US 2003-651723	20030829	<--
PRAI	US 1998-105371P	P	19981023 <--			
	US 1999-428082	A	19991022 <--			
	WO 1999-US25044	W	19991025 <--			

AB The present invention concerns fusion of Fc domains with biol. active peptides and a process for preparing pharmaceutical agents using biol. active peptides. In this invention, pharmacol. active compds. are prepared by a process comprising: (a) selecting at least one peptide that modulates the activity of a protein of interest; and (b) preparing a pharmacol. agent comprising an Fc domain covalently linked to at least one amino acid of the selected peptide. Linkage to the vehicle increases the half-life of the peptide, which otherwise would be quickly degraded in vivo. The preferred vehicle is an Fc domain. The peptide is preferably selected by phage display, Escherichia coli coli display, ribosome display, RNA-peptide screening, or chemical-peptide screening.

IT **268228-17-7D**, fusion protein with IgG1 Fc domain
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(calmodulin antagonist; modified peptides containing an antibody Fc domain as therapeutic agents)

L31 ANSWER 34 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:172837 HCAPLUS
DN 132:221339
TI Methods for making HLA binding peptides and their uses
IN Kubo, Ralph T.; Grey, Howard M.; Sette, Alessandro; Celis, Esteban
PA Epimmune Inc., USA
SO U.S., 329 pp., Cont.-in-part of U.S. Ser. No. 103,396, abandoned.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 17

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	US 6037135	A	20000314	US 1993-159339	19931129	<--
	US 5662907	A	19970902	US 1994-186266	19940125	<--
	US 2002168374	A1	20021114	US 1997-821739	19970320	<--
	US 6689363	B1	20040210	US 1999-239043	19990127	<--
PRAI	US 1992-926666	B2	19920807 <--			
	US 1993-27746	B2	19930305 <--			
	US 1993-103396	B2	19930806 <--			
	US 1992-827682	B2	19920129 <--			
	US 1992-874491	B2	19920427 <--			
	US 1992-935811	B2	19920826 <--			
	US 1993-27146	B2	19930305 <--			
	US 1993-73205	B2	19930604 <--			
	US 1993-159184	B2	19931129 <--			
	US 1993-159339	A2	19931129 <--			
	US 1994-197484	A2	19940216 <--			
	US 1994-205713	A2	19940304 <--			
	US 1994-278634	B2	19940721 <--			
	US 1994-344824	A2	19941123 <--			
	US 1994-347610	A2	19941201 <--			
	US 1995-461603	A1	19950605 <--			
	US 1996-13363P	P	19960313 <--			
	US 1996-13833P	P	19960321 <--			
	US 1997-820360	A2	19970312 <--			
	US 1997-978291	A2	19971125 <--			
	US 1998-189702	A2	19981110 <--			

AB Disclosed are methods for making peptides comprising an HLA-A24.1-,

HLA-A1-, HLA-A11-, and HLA-A3.2-restricted T cell epitope consisting of about 8-11 amino acid residues, and methods of making a peptide that binds to an HLA-A24.1, HLA-A1, HLA-A11, and HLA-A3.2 mol. at a dissociation constant of less than 500 nM. Epitopes on a number of potential target proteins (e.g. prostate specific antigen, hepatitis B core and surface antigens, hepatitis C antigen, malignant melanoma antigen MAGE-1, Epstein-Barr virus antigens, HIV-1 and papilloma virus antigen) are identified. These HLA-binding peptides are useful for treating and diagnosing a number of pathol. states such as viral infection and cancer.

IT **165394-55-8**
RL: BSU (Biological study, unclassified); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(HLA binding epitopes of viral and tumor antigen for treatment and diagnosis)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Bruss, V	1997	71	9350	J Virology	HCAPLUS
Carreno, B	1990	87	3420	Proc Natl Acad Sci U	HCAPLUS
Cordingley	1990	265	9062	J B C	HCAPLUS
de Bruijn, M	1991	21	2963	Eur J Immunol	HCAPLUS
Engelhard, V	1994	12	181	Annu Rev Immunol	HCAPLUS
Engelhard, V	1994	6	13	Curr Opin Immunol	HCAPLUS
Falk, K	1991	351	290	Nature	HCAPLUS
Henderson, R	1992	255	1264	Science	HCAPLUS
Hunt, D	1992	255	1261	Science	HCAPLUS
Jardetzky, T	1991	353	326	Nature	HCAPLUS
Kannagi, M	1992	66	2928	J of Virol	HCAPLUS
Kumar, V	1990	87	1337	PNAS	HCAPLUS
Maryanski, J	1990	60	63	Cell	HCAPLUS
Maryanski, J	1990	60	63	Cell	HCAPLUS
Maryanski, J	1988	167	1391	J Exp Med	HCAPLUS
Morrison, J	1992	22	903	Eur J Immunol	HCAPLUS
Pamer, E	1991	353	852	Nature	HCAPLUS
Parham, P	1995	143	141	Immunological Review	HCAPLUS
Parker, K	1992	267	5451	J Biol Chem	HCAPLUS
Parker, K	1992	149	3580	J Immunol	HCAPLUS
Patarroyo, M	1987	328	629	Nature	HCAPLUS
Paul, W	1989		473	Fundamental Immunolo	
Paul, W	1993		617	Fundamental Immunolo	
Paul, W	1999		274	Fundamental Immunolo	
Preisler-Adams, S	1993	21	2258	Nucleic Acids Res	HCAPLUS
Rammensee, H	1993	11	213	Annu Rev Immunol	HCAPLUS
Rotzschke, O	1991	12	447	Immunology Today	MEDLINE
Shimojo, N	1989	143	2939	J of Immunol	MEDLINE
Urban, J	1989	59	257	Cell	HCAPLUS
van Eden	1989	89	33	Vaccines	
van der Zee	1989	19	43	Eur J Immunology	HCAPLUS
Wraith, D	1989	59	247	Cell	HCAPLUS

L31 ANSWER 35 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:83111 HCAPLUS
DN 132:146627
TI Synthetic peptide antibiotics, especially for inhibiting the growth of fungi in plants or animals
IN Edwards, David
PA NCE Pharmaceuticals, Inc., USA
SO U.S., 27 pp., Cont.-in-part of U.S. 5,602,097.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6020312	A	20000201	US 1996-767903	19961217 <--
	US 5602097	A	19970211	US 1994-305768	19940913 <--
	WO 9608264	A1	19960321	WO 1995-US11724	19950913 <--
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM				
	RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5885782	A	19990323	US 1997-871163	19970609 <--
	WO 9826793	A1	19980625	WO 1997-US23182	19971216 <--
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9856059	A1	19980715	AU 1998-56059	19971216 <--
	AU 732322	B2	20010412		
	EP 948344	A1	19991013	EP 1997-952463	19971216 <--
	R: BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE, IE				
	NZ 336742	A	20030725	NZ 1997-336742	19971216 <--
PRAI	US 1994-305768	A2	19940913 <--		
	WO 1995-US11724	A2	19950913 <--		
	US 1996-767903	A2	19961217 <--		
	WO 1997-US23182	W	19971216 <--		

AB Compns. are provided for inhibiting the growth of microorganisms, particularly fungi. The compns. consist of chemical-synthesized antibiotics comprising certain amino acids. Methods of identifying particular antibiotic compns. from libraries of such compns. are disclosed. In addition, methods for preventing microbial growth in plants and animals are disclosed.

IT **256651-29-3D**, D- and L-amino acid analogs
RL: AGR (Agricultural use); **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(peptide antibiotics, especially for inhibiting fungal growth in plant or animal)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon	1992			WO 9209300	HCAPLUS
Anon	1994			WO 9408010	HCAPLUS
Anon	1998			International Search	
Blondelle	1995			US 5440016	
Blondelle	1994	38	2280	Antimicrobial Agents	HCAPLUS
Broekaert	1998			US 5773694	HCAPLUS
Broekaert, W	1992	31	4308	Biochem	HCAPLUS
Broekaert, W	1990	69	55	Fed Eur Microbiol So	HCAPLUS
Cammue	1992	267	2228	J Biol Chem	HCAPLUS
Duchesne	1993	95	630	Biochem Biophys Res	
Edwards	1990			US 4948734	HCAPLUS
Edwards	1992			US 5093120	HCAPLUS
Edwards	1997			US 5620047	
Geysen	1989			US 4833092	HCAPLUS
Howell	1980	70	712	Phytopathology	HCAPLUS
Huebner	1993			US 5182366	HCAPLUS

Janisiewicz	1991	75	490	Plant Dis	HCAPLUS
Janisiewicz, W	1988	78	1697	Phytopathology	
Janisiewicz, W	1988	78	194	Phytopathology	
Khananshvili	1993	268	200	JBC	HCAPLUS
Lim	1982			US 4324683	HCAPLUS
Masterman	1997			US 5616315	HCAPLUS
Mor	1989	13	51	Neuropeptides	HCAPLUS
Ohba	1987	XL	709	J Antibiotics	
Olstein	1998			US 5750357	HCAPLUS
Roberts	1997			US 5703044	HCAPLUS
Rutter	1991			US 5010175	HCAPLUS
Sagan	1989	163	726	Biochem Biophys Res	HCAPLUS
Terras	1993	316	233	FEBS	HCAPLUS
Terras	1992	267	15301	J Biol Chem	HCAPLUS
Wilcox	1994			US 5290914	HCAPLUS

L31 ANSWER 36 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:10571 HCAPLUS
DN 132:74502
TI Gene therapy of genetic or infectious diseases by small fragment homologous replacement
IN Gruenert, Deiter C.; Kunzelmann, Karl
PA The Regents of the University of California, USA
SO U.S., 65 pp., Cont.-in-part of U.S. Ser. No. 409,544, abandoned.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE	
PI	US 6010908	A	20000104		US 1995-487799	19950607	<--
	US 5804383	A	19980908		US 1996-727003	19961008	<--
PRAI	US 1992-933471	B1	19920821	<--			
	US 1995-409544	B2	19950324	<--			
	US 1995-487799	A2	19950607	<--			

AB A method for gene therapy of genetic or infectious disease using small fragment homologous replacement is described. The method introduces small fragments of exogenous DNA into regions of endogenous genomic DNA virtually homologous to the exogenous DNA. The exogenous DNA fragments contains sequence modification that correct mutations in the endogenous DNA or introduce mutations that alter cellular or an infecting pathogen phenotype. The method is tested to correct the δF508 mutation found in exon 10 of CFTR gene in vitro in an immortalized cell line ΣCFTE29o- derived from a cystic fibrosis patient with two δF508 alleles. The defect was corrected by transfecting ΣCFTE29o- with 491 nucleotide recA-coated CFTR ssDNA fragment containing exon 10 and flanking introns by a number of techniques. Allelic-specific PCR was used to assess the homologous recombination frequency. This method was also evaluated in vivo using a transgenic mouse expressing a mutant mouse CFTR gene. The same strategy was provided for the treatment of other genetic diseases including classical sickle cell anemia and Xeroderma pigmentosum. The advantage of this method is that it can overcome the drawback of complementation technique by placing the completely repaired sequence under the control of the endogenous gene promoter so that the correct gene is expressed at appropriate levels in the cell.

IT **253674-07-6**
RL: ARG (Analytical reagent use); PRP (Properties); ANST (Analytical study); USES (Uses)
(Unclaimed PCR primer; gene therapy of genetic or infectious diseases by small fragment homologous replacement)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File

Alton, E	1994	8	8	Nature Genetics	MEDLINE
Anon	1989		16.30	Molecular Cloning: A	
Anon	1995	1	182	Nature Medicine	
Bertling	1990			US 4950599	HCAPLUS
Boucher, R	1994	5	516	Human Gene Therapy	
Caplen, N	1995	1		Nature Medicine	HCAPLUS
Cline	1985	29	69	Pharm Ther	HCAPLUS
Erickson, D	1992		112	Scientific American	MEDLINE
Flotte, T	1995	2	29	Gene Therapy	HCAPLUS
Gareis, M	1991	37	191	Cell Mol Biol	HCAPLUS
Goldman, M	1995	9		Nature Genetics	HCAPLUS
Logan, J	1995	2	38	Gebe Therapy	MEDLINE
Palca, J	1994		79	Discover	
Shesely	1991			Proceedings of the N	
Sorscher, E	1994	5	1259	Human Gene Therapy	MEDLINE
Vega	1991	87	245	Human Genetics	HCAPLUS
Wilson, J	1994	5	501	Human Gene Therapy	MEDLINE
Wilson, J	1993	365	691	Nature	MEDLINE
Wolf, M	1991	13	390	Applied Biochem	
Zabner, J	1993	75	207	Cell	HCAPLUS

L31 ANSWER 37 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:808585 HCAPLUS
DN 132:44952
TI Method of identifying compounds that regulate the binding of Mycobacterium tuberculosis sigF to M. tuberculosis orfX
IN Bishai, William R.; Young, Douglas B.; Zhang, Ying; Demaio, James
PA Johns Hopkins University, USA
SO U.S., 27 pp., Cont.-in-part of U.S. 5,824,546.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6004764	A	19991221	US 1997-826390	19970409 <--
	US 5700925	A	19971223	US 1996-622353	19960327 <--
	US 5824546	A	19981020	US 1996-622352	19960327 <--
	CA 2249208	AA	19971002	CA 1997-2249208	19970327 <--
PRAI	US 1996-622352	A2	19960327 <--		
	US 1996-622353	A2	19960327 <--		

AB SigF is a gene that controls M. tuberculosis latency. A diagnostic test for latent tuberculosis involves detecting M. tuberculosis sigF in clin. specimens. Two genes orfX and orfY regulate sigF expression and sigF activity. M. tuberculosis sigF, orfX, and orfY are used in screening methods for potential therapeutic agents which regulate the growth of M. tuberculosis.
IT **252897-82-8**
RL: PRP (Properties)
(unclaimed sequence; method of identifying compds. that regulate the binding of Mycobacterium tuberculosis sigF to M. tuberculosis orfX)
RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Alper	1994	77	195	Cell	HCAPLUS
Ausubel	1994		1.8.4	Current Protocols in	
Barksdale	1973	54	290	Biochem Biophys Res	MEDLINE
Bashyam	1996	178	4847	J Bateriol	HCAPLUS
Benson	1993	175	2347	J Bacteriol	HCAPLUS
Benson	1993	90	2330	Proc Natl Acad Sci	HCAPLUS
Bishai	1996	334	1572	New Eng J Med	

Bloom	1992	257	1055	Science	MEDLINE
Boylan	1993	175	3957	J Bacteriol	HCAPLUS
Burgess	1971	21	500	Methods Enzymol	HCAPLUS
Chatterjee	1976	48	398	Leprosy in India	MEDLINE
Collins	1995	92	8036	Proc Natl Acad Sci	HCAPLUS
Csillag	1964	34	341	J Gen Microbiol	
Curcic	1994	13	1057	Mol Microbiol	HCAPLUS
DeMaio	1996	93	2790	Proc Natl Acad Sci	HCAPLUS
DeMaio	1997	78	1	Tubercle and Lung Di	
Dhandayuthapani	1995	17	901	Mol Microbiol	HCAPLUS
Dufour	1994	176	1813	J Bacteriol	HCAPLUS
Errington	1986	132	2967	J Gen Microbiol	HCAPLUS
Fidler	1993	306	546	Brit Med J	MEDLINE
Firestein	1987	167	381	Anal Biochem	HCAPLUS
Gedde-Dahl	1952	56	139	Am J Hyg	MEDLINE
Gholamhoseinian	1989	171	5747	J Bacteriol	HCAPLUS
Gordon	1994	19	336	Lett Appl Microbiol	HCAPLUS
Gross	1992	1	129	Transcriptional Regu	
Haines	1992	12	736	Biotechniques	HCAPLUS
Haldenwang	1995	59	1	Microbiol Rev	HCAPLUS
Honore	1993	7	207	Mol Microbiol	HCAPLUS
Kalman	1990	172	5575	J Bacteriol	HCAPLUS
Kempsell	1992	138	1717	Gen Microbiol	HCAPLUS
Khomenko	1980	2	18	Probl Tuberk	
Khomenko	1987	68	243	Tubercle	MEDLINE
Kumar	1988	15	235	J Biochem Biophys Me	HCAPLUS
Lonetto	1992	174	3843	J Bacteriol	HCAPLUS
Lonetto	1994	91	7573	Proc Natl Acad Sci	HCAPLUS
Margolis	1991	254	562	Science	HCAPLUS
Min	1993	74	735	Cell	HCAPLUS
Moran	1990		267	Molecular Biological	
Ngo			492	Birkhauser	
Ngo	1994		433	Birkhauser	HCAPLUS
Potuckova	1995	17	37	Mol Microbiol	HCAPLUS
Predich	1995	15	355	Mol Microbiol	HCAPLUS
Rook	1992	13	160	Immunol Today	HCAPLUS
Samrook	1989		9.31	Molecular Cloning: A	
Schmidt	1990	87	9221	Proc Natl Acad Sci	HCAPLUS
Schuler	1991	9	180	Proteins: Struct Fun	HCAPLUS
Smith	1994		47	Tuberculosis: Pathog	
Spiegelman	1974	249	1476	J Biol Chem	HCAPLUS
Stanford	1987	68	241	Tubercle	MEDLINE
Stock	1989	53	450	Microbiol Rev	HCAPLUS
Sudre	1992	70	149	Bull WHO	MEDLINE
Tanaka	1988	242	1040	Science	HCAPLUS
Wayne	1976	114	807	Am Rev Respiratory D	HCAPLUS
Wayne	1994	13	908	Eur J Clin Microbiol	MEDLINE
Werner	1953	69	473	Am Rev Tuberculosis	
Wu	1989	171	692	J Bacteriol	HCAPLUS

L31 ANSWER 38 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:794209 HCAPLUS
DN 132:34756
TI Mycobacterium vaccae antigens
IN Tan, Paul; Hiyama, Jun; Visser, Elizabeth; Skinner, Margot; Scott, Linda; Prestidge, Ross
PA Genesis Research & Development Corporation Limited, N. Z.
SO U.S., 69 pp., Cont.-in-part of U.S. Ser. No. 705,347.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 8

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

```
     ---------------  ----  --------       ---------------  --------
PI   US 6001361         A    19991214       US 1997-873970   19970612 <--
     US 6284255         B1   20010904       US 1996-705347   19960829 <--
     WO 9808542         A2   19980305       WO 1997-NZ105    19970828 <--
     WO 9808542         A3   19980709
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ,
             VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
             GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
             GN, ML, MR, NE, SN, TD, TG
     AU 9740365         A1   19980319       AU 1997-40365    19970828 <--
     AU 723606          B2   20000831
     EP 939646          A2   19990908       EP 1997-937915   19970828 <--
         R:  CH, DE, DK, FR, GB, IT, LI, NL, SE
     CN 1235555         A    19991117       CN 1997-199228   19970828 <--
     BR 9711457         A    20000118       BR 1997-11457    19970828 <--
     NZ 334358          A    20000825       NZ 1997-334358   19970828 <--
     JP 2001503969      T2   20010327       JP 1998-511516   19970828 <--
     US 5985287         A    19991116       US 1997-997362   19971223 <--
     ZA 9801148         A    19980820       ZA 1998-1148     19980212 <--
     TW 527360          B    20030411       TW 1998-87102509 19980220 <--
     US 6160093         A    20001212       US 1998-95855    19980611 <--
     US 6410720         B1   20020625       US 1998-200643   19981105 <--
     US 6406704         B1   20020618       US 1998-205426   19981204 <--
     KR 2000037134      A    20000705       KR 1999-701705   19990302 <--
     AU 741016          B2   20011122       AU 2000-42588    20000621 <--
PRAI US 1996-705347     A2   19960829  <--
     US 1997-873970     A    19970612  <--
     WO 1997-NZ105      W    19970828  <--
     US 1997-997362     A2   19971223  <--
     US 1998-95855      A2   19980611  <--
```

AB The present invention provides polypeptides comprising an immunogenic portion of a M. vaccae soluble protein and DNA mols. encoding such polypeptides, together with methods for their use in the diagnosis and treatment of mycobacterial infection. Methods for enhancing the immune response to an antigen including administration of M. vaccae culture filtrate or delipidated M. vaccae cells are also provided. Thus, effect of immunization of mice with Mycobacterium vaccae on tuberculosis was tested, and several M. vaccae culture filtrate-derived polypeptides (GVc-1, GVc-2, GVc-7, GVc-13, GVc-20, GVc-22, GVc-12, GVc-14, GVc-15, GVc-17, GVs-1, GVs-3, GVs-4, GVs-5, GVs-6, GVs-8, GVs-9, etc.) were purified and characterized.

IT **252321-33-8**
RL: PRP (Properties)
(unclaimed protein sequence; mycobacterium vaccae antigens)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Adam	1977			US 4036953	HCAPLUS
Anon	1990			WO 9002564	
Anon	1990			WO 9007935	HCAPLUS
Anon	1991			WO 9101751	
Anon	1991			WO 9102542	HCAPLUS
Anon	1992			WO 9208484	
Anon	1992			WO 9208488	
Anon	1993			WO 9316727	
Anon	1994			WO 9406466	HCAPLUS
Anon	1995			WO 9514713	HCAPLUS
Anon	1995			WO 9525744	HCAPLUS

Anon	1995			WO 9526742	
Anon	1997			EP 0763361	
Burgess	1990	111	2129	J Cell Biol	HCAPLUS
Fox	1989			US 4879213	HCAPLUS
Jolles	1976			US 3956481	HCAPLUS
Lazen	1988	8	1247	Mol Cell Biol	
Rook	1988			US 4724144	
Skinner	1997	65	4525	Infection and Immuni	HCAPLUS
Stanford	1987			US 4716038	HCAPLUS
Stanford	1997			US 5599545	
White, R	1958	I	54	Immunology	
White, R	1964	7	158	Immunology	
White, R	1967	6	49	Symposium Series Imm	
Wiker	1990	58	272	Injection & Immunity	HCAPLUS

L31 ANSWER 39 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:547466 HCAPLUS
DN 131:296707
TI Identification of an **.alpha.3.beta.1 integrin** recognition sequence in thrombospondin-1
AU **Krutzsch, Henry C.**; Choe, Bertrand J.; Sipes, John M.; Guo, Neng-Hua; **Roberts, David D.**
CS Laboratory of Pathology, NCI, National Institutes of Health, Bethesda, MD, 20892, USA
SO Journal of Biological Chemistry (**1999**), 274(34), 24080-24086
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English
AB A synthetic peptide containing amino acid residues 190-201 of thrombospondin-1 (TSP1) promoted adhesion of MDA-MB-435 breast carcinoma cells when immobilized and inhibited adhesion of the same cells to TSP1 when added in solution Adhesion to this peptide was enhanced by a β **1 integrin**-activating antibody, Mn2+, and insulin-like growth factor I and was inhibited by an **.alpha.3. beta.1 integrin** function-blocking antibody. The soluble peptide inhibited adhesion of cells to the immobilized TSP1 peptide or spreading on intact TSP1 but at the same concns. did not inhibit attachment or spreading on type IV collagen or fibronectin. Substitution of several residues in the TSP1 peptide with Ala residues abolished or diminished the inhibitory activity of the peptide in solution, but only substitution of Arg-198 completely inactivated the adhesive activity of the immobilized peptide. The essential residues for activity of the peptide as a soluble inhibitor are Asn-196, Val-197, and Arg-198, but flanking residues enhance the inhibitory activity of this core sequence, either by altering the conformation of the active sequence or by interacting with the **integrin.** This functional sequence is conserved in all known mammalian TSP1 sequences and in TSP1 from Xenopus laevis. The TSP1 peptide also inhibited adhesion of MDA-MB-435 cells to the laminin-1 peptide GD6, which contains a potential **integrin** -recognition sequence Asn-Leu-Arg and is derived from a similar position in a pentraxin module. Adhesion studies using recombinant TSP1 fragments also localized **.beta.1 integrin**-dependent adhesion to residues 175-242 of this region, which contain the active sequence.
IT **247111-59-7 247111-60-0 247111-61-1 247111-63-3 247111-64-4 247111-65-5 247111-66-6 247111-67-7 247111-68-8 247111-69-9 247111-70-2 247111-74-6 247111-78-0**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)

(model peptide, effect on adhesion; identification of an
α 3β **1 integrin**
recognition sequence in thrombospondin-1)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Adachi, M	1998	16	1060	J Clin Oncol	HCAPLUS
Adams, J	1995	108	1977	J Cell Sci	HCAPLUS
Akiyama, S	1985	260	4492	J Biol Chem	HCAPLUS
Aota, S	1995	70	1	Adv Enzymol Relat Ar	HCAPLUS
Beckmann, G	1998	275	725	J Mol Biol	HCAPLUS
Chandrasekaran, S	1999	274	11408	J Biol Chem	HCAPLUS
Clezardin, P	1997	321	819	Biochem J	HCAPLUS
Dawson, D	1997	138	707	J Cell Biol	HCAPLUS
DeFreitas, M	1995	15	333	Neuron	HCAPLUS
Delwel, G	1994	5	203	Mol Biol Cell	HCAPLUS
Eble, J	1998	37	10945	Biochemistry	HCAPLUS
Elices, M	1991	112	169	J Cell Biol	HCAPLUS
Emsley, J	1994	367	338	Nature	HCAPLUS
Fernandez, C	1998	3	684	Frontiers Biosci	
Gao, A	1996	271	21	J Biol Chem	HCAPLUS
Gehlsen, K	1992	117	449	J Cell Biol	HCAPLUS
Gresham, H	1996	271	30587	J Biol Chem	HCAPLUS
Guo, N	1992	267	19349	J Biol Chem	HCAPLUS
Guo, N	1997	50	210	J Peptide Res	HCAPLUS
Guo, N	1992	89	3040	Proc Natl Acad Sci U	HCAPLUS
Hemler, M	1990	32	229	Cell Differ Dev	HCAPLUS
Hemler, M	1984	132	3011	J Immunol	HCAPLUS
Kreidberg, J	1996	122	3537	Development	HCAPLUS
Krukonis, E	1998	273	31837	J Biol Chem	HCAPLUS
Lawrence, C	1993	262	208	Science	HCAPLUS
Legrand, C	1992	79	1995	Blood	HCAPLUS
Miles, A	1995	270	29047	J Biol Chem	HCAPLUS
Mizushima, H	1997	8	979	Cell Growth Differ	HCAPLUS
Murphy-Ullrich, J	1993	268	26784	J Biol Chem	HCAPLUS
Prater, C	1991	112	1031	J Cell Biol	HCAPLUS
Roberts, D	1994	16	217	J Tissue Culture Met	
Ruoslahti, E	1996	12	697	Annu Rev Cell Dev Bi	HCAPLUS
Schuler, G	1991	9	180	Prot Struct Funct Ge	HCAPLUS
Shrive, A	1996	3	346	Nat Struct Biol	HCAPLUS
Sipes, J	1999	274	22755	J Biol Chem	HCAPLUS
Stahl, S	1997	110	55	J Cell Sci	HCAPLUS
Vogel, T	1993	53	74	J Cell Biochem	HCAPLUS
Weitzman, J	1996	4	41	Cell Adhes Commun	HCAPLUS
Weitzman, J	1993	268	8651	J Biol Chem	HCAPLUS
Wu, C	1995	108	2511	J Cell Sci	HCAPLUS
Yamada, K	1991	266	12809	J Biol Chem	HCAPLUS

L31 ANSWER 40 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:483302 HCAPLUS
DN 131:125480
TI Bordetella pertussis filamentous hemagglutinin-based peptides which inhibit adhesion between leukocytes and endothelial cells
IN Tuomanen, Elaine; Masure, H. Robert
PA The Rockefeller University, USA
SO U.S., 82 pp.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI US 5932217 A 19990803 US 1994-348353 19941130 <--
EP 584273 A1 19940302 EP 1992-913635 19920504 <--
EP 584273 B1 19981230
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE
JP 06507641 T2 19940901 JP 1992-512001 19920504 <--
AU 664849 B2 19951207 AU 1992-21687 19920504 <--
AU 9221687 A1 19921221
AT 175122 E 19990115 AT 1992-913635 19920504 <--
US 5792457 A 19980811 US 1995-465929 19950606 <--
US 5968512 A 19991019 US 1995-465965 19950606 <--
US 6015560 A 20000118 US 1995-465966 19950606 <--
PRAI US 1994-247572 B2 19940523 <--
US 1991-695613 A 19910503 <--
WO 1992-US3725 W 19920504 <--
US 1994-348353 A3 19941130 <--

AB Peptides which will inhibit the reaction between the RGD tripeptide of Bordetella pertussis filamentous hemagglutinin (FHA) and the **integrin** receptors of endothelial cells and their utility as therapeutic agents are described. FHA is discovered to comprise polypeptide regions with binding properties homologous to those of C3bi, blood-coagulation factor X, and an **integrin** receptor on endothelial cells. They are also antigenically related and antibodies to FHA cross-react with endothelial cells. Peptide regions of FHA can bind to leukocytes and competitively inhibit binding of Factor X or C3bi to leukocytes or leukocytes to endothelial cells. Significant consequences of these discoveries are: (1) peptides which contain or are analogs of the RGD region or one of the Factor X regions of FHA will bind to the CR3 **integrin** of leukocytes, thereby preventing adherence of the leukocyte to endothelial cells in a procedure for lessening deleterious inflammation; (2) peptides or analogs which interact with leukocytes in competition with Factor X or C3bi can be used to inhibit blood coagulation or opsonization and phagocytosis; (3) antibodies to FHA will bind to homologous regions of normal proteins in animals; (4) peptides containing the carbohydrate recognition domain or analogs are optimal vaccines for whooping cough; and (5) peptides of each of the endothelial cell **integrin** receptor, Factor X, or C3bi domains of FHA are useful in vaccine quality control.

IT **233665-31-1**
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(Bordetella pertussis filamentous hemagglutinin-based peptides which inhibit adhesion between leukocytes and endothelial cells)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Altieri	1991	254	1200	Science	HCAPLUS
Delisse-Gathoye	1990	58	2895	Infect Immun	HCAPLUS
Graf	1987	26	6896	Biochemistry	HCAPLUS
Kimura	1990	58	7	Infection and Immuni	HCAPLUS
Murphy	1994	303	619	Biochem J	HCAPLUS
Parsons, J	1976		1	Peptide Hormones	
Quagliarello And Scheld	1992	327	864	N Engl J Med	
Relman	1990	61	1375	Cell	HCAPLUS
Relman	1989	86	2637	Proc Natl Acad Sci U	HCAPLUS
Saukkonen	1991	173	1143	J Exp Med	HCAPLUS
Tuomanen	1988	168	267	J Exp Med	HCAPLUS
Tuomanen	1989	170	959	J Exp Med	MEDLINE
Tuomanen	1985	151	859	J Infect Dis	HCAPLUS
Tuomanen And Weiss	1985	152	118	J Infect Dis	

L31 ANSWER 41 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:147365 HCAPLUS
DN 130:205126
TI Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX
IN Miller, Jonathan L.; Lyle, Vicki A.
PA The Research Foundation of State University of New York, USA
SO U.S., 52 pp., Cont.-in-part of U.S. Ser. No. 406,330.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5877155	A	19990302	US 1995-556597	19951113 <--
	US 5817748	A	19981006	US 1995-406330	19950317 <--
	WO 9718236	A1	19970522	WO 1996-US17882	19961108 <--
	W: CA, CN, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 876396	A1	19981111	EP 1996-942734	19961108 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1202175	A	19981216	CN 1996-198270	19961108 <--
	JP 2001511111	T2	20010807	JP 1997-518928	19961108 <--
PRAI	US 1995-406330	A2	19950317 <--		
	US 1995-556597	A	19951113 <--		
	WO 1996-US17882	W	19961108 <--		

AB The invention is directed to an isolated peptide that functionally mimics a binding site for a monoclonal antibody, the monoclonal antibody recognizing an epitope within the human platelet glycoprotein Ib/IX complex. This peptide is called a mimotope. The invention also provides an isolated mol. capable of binding to the peptide, or the mimotope, which mol. can be an antibody, a second peptide, a carbohydrate, a DNA mol., an RNA mol., or other naturally or chemical synthesized mols. This isolated mol. is called an anti-mimotope. Mimotopes mimicking the binding site for monoclonal antibody C-34 and SZ-2, as well as anti-mimotopes to the C-34 mimotopes, are specifically provided. The anti-mimotopes could serve as antithrombotic drugs.

IT **190831-63-1**
RL: PRP (Properties)
(mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon	1991			WO 9109614	HCAPLUS
Anon	1992			WO 9209302	HCAPLUS
Balass, M	1993	90	10638	Proc Natl Acad Sci U	HCAPLUS
Califf, R	1994	330	956	New England Journal	
Christian, R	1992	227	711	J Mol Biol	HCAPLUS
Collen, D	1994	71	95	Thrombosis and Haemo	HCAPLUS
Coller, B	1992	43	171	Annu Rev Med	HCAPLUS
Cwirla, S	1990	87	6378	Proc Natl Acad Sci U	HCAPLUS
Ganderton, R	1992	288	195	Biochem J	HCAPLUS
Ginsberg	1993			US 5177188	HCAPLUS
Hobart, M	1993	252	157	Proc R Soc London B	HCAPLUS
Jennings, L	1994	84	72a	Abstract #278, Blood	
Joyce, G	1994	4	331	Current Opinion in S	HCAPLUS
Larocca, D	1992	11	191	Hybridoma	HCAPLUS
Lenstra, J	1992	152	149	J Immunol Methods	HCAPLUS
Miller, J	1991	11	1231	Arteriosclerosis and	HCAPLUS
Miller, J	1990	74	313	Br J Haemotol	HCAPLUS
Mousa, A	1994	89	3	Circulation	
Otey, C	1993	268	21193	The Journal of Biolo	HCAPLUS
Pearson, W	1990	183	63	Methods in Enzymolog	HCAPLUS

Pearson, W	1988	85	2444	Proc Natl Acad Sci U	HCAPLUS
Phillips, D	1991	65	359	Cell	HCAPLUS
Plow	1992			US 5114842	HCAPLUS
Rote, W	1994	23	681	Journal of Cardiovas	HCAPLUS
Scott, J	1990	249	386	Science	HCAPLUS
Scott, J	1992	17	241	Trends in Biochem Sc	HCAPLUS
Smith, G	1993	217	228	Methods in Enzymolog	HCAPLUS
South, V	1995	73	144	Thrombosis and Haemo	HCAPLUS
Turner, N	1994	84	72a	Abstract #967, Blood	

L31 ANSWER 42 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:785570 HCAPLUS
DN 130:37293
TI Synthetic chimeric fimbrin peptides
IN Bakaletz, Lauren O.; Kaumaya, Pravin T. P.
PA The Ohio State University, USA
SO U.S., 16 pp.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5843464	A	19981201	US 1995-460502	19950602 <--
	US 6436405	B1	20020820	US 1998-148711	19980904 <--
	US 2003113344	A1	20030619	US 2002-223711	20020819 <--
PRAI	US 1995-460502	A1	19950602 <--		
	US 1998-148711	A3	19980904 <--		

AB The present invention provides synthetic chimeric fimbrin peptides which induce an immunogenic response in animals to non-typable Haemophilus influenzae and that do not require tedious purification techniques. The synthetic chimeric fimbrin peptides reduce the severity of otitis media caused by Haemophilus influenzae. The synthetic chimeric fimbrin peptides are synthesized using com. available peptide synthesizers. The synthetic chimeric fimbrin peptides comprises three peptide units. The first peptide unit is a subunit of the fimbrin protein. The second peptide unit is a T cell epitope. The third peptide unit is a linker peptide unit which joins the first and second peptide unit. The linking sequence preferably has from about 2 to about 15 amino acids, more preferably from about 2 to about 10 amino acids, most preferably from about 5 to about 6 amino acids. The synthetic chimeric fimbrin peptides are useful immunogens against NTHi and also useful as laboratory tool for detecting antibodies in sera. The invention also relates to an immunogenic composition containing the synthetic chimeric fimbrin peptides and a pharmacol. acceptable carrier.

IT **216757-45-8P**
RL: PRP (Properties); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(linker; chimeric fimbrin peptides for reducing otitis media caused by Haemophilus influenzae and for detecting anti-Haemophilus influenzae antibodies in sera)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon	1994			WO 9426304	HCAPLUS
Bakaletz, L	1990			90th Annual Meeting	
Bakaletz, L	1993			American Society for	
Bakaletz, L	1993			Eleventh Midwinter R	
Bakaletz, L	1991			Fifth International	
Bakaletz, L	1991			Fourteenth Midwinter	
Bakaletz, L	1992			Molecular Biology of	
Bakaletz, L	1993			Second Extraordinary	

Bakaletz, L	1990			Thirteenth Midwinter	
Bakaletz, L	1990			Thirteenth Midwinter	
Bakaletz, L	1989			Twelfth Midwinter Re	
Balaketz, L	1991			Fifth International	
DeMaria, T	1991			Fifth International	
Deich	1992			US 5110908	HCAPLUS

L31 ANSWER 43 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:719131 HCAPLUS
DN 130:4085
TI Preparation of peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria
IN Gray, Beulah H.; Haseman, Judith R.; Mayo, Kevin H.
PA Regents of the University of Minnesota, USA
SO U.S., 56 pp., Cont.-in-part of U.S. Ser. No. 218,026.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5830860	A	19981103	US 1996-653632	19960524 <--
	US 5786324	A	19980728	US 1994-218026	19940324 <--
	WO 9744354	A2	19971127	WO 1997-US8944	19970523 <--
	W: CA, JP, US, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 939766	A2	19990908	EP 1997-928665	19970523 <--
	R: DE, FR, GB, IT, SE				
	JP 2000511892	T2	20000912	JP 1997-542843	19970523 <--
	US 6486125	B1	20021126	US 1999-194296	19991015 <--
	US 2003153502	A1	20030814	US 2002-300083	20021120 <--
PRAI	US 1994-218026	A2	19940324 <--		
	US 1996-653632	A2	19960524 <--		
	US 1996-671487	A2	19960627 <--		
	WO 1997-US8944	W	19970523 <--		
	US 1999-194296	A3	19991015 <--		

AB The invention provides biol. active peptides derived from or corresponding to regions of a bactericidal permeability increasing factor (B/PI). The peptides are preferably about 10 to 100 amino acids long and have bactericidal and/or endotoxin neutralizing activity. The peptides can be prepared by automated protein synthesis or by recombinant DNA methods. The peptides are useful in methods to treat and prevent bacterial infection in the body and on surfaces. The peptides are also useful to treat endotoxin shock and have endotoxin neutralizing activity.
IT **164584-39-8P**
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); SPN (Synthetic preparation); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides with bactericidal activity and endotoxin neutralizing activity for gram neg. bacteria)
RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon	1989			WO 8901486	HCAPLUS
Anon	1990			WO 9009183	HCAPLUS
Anon	1992			WO 9209621	HCAPLUS
Anon	1993			WO 9305797	HCAPLUS
Anon	1993			WO 9323434	HCAPLUS
Anon	1994			WO 9417819	HCAPLUS
Anon	1994			WO 9418323	HCAPLUS
Anon	1994			WO 9420532	HCAPLUS

Anon	1994			WO 9425476	HCAPLUS
Anon	1995			WO 9500641	HCAPLUS
Anon	1995			WO 9501428	HCAPLUS
Anon	1995			WO 9502414	HCAPLUS
Bangalore	1990	265	13584	J Biol Chem	HCAPLUS
Bottone	1975	1	425	J Clin Micro	MEDLINE
Brown	1979	68	109	Methods in Enzymolog	HCAPLUS
Campanelli	1990	85	904	J Clin Invest	HCAPLUS
Capone	1989	6	62	Gene Anal Techn	HCAPLUS
Casey	1986	52	384	Infect Immun	HCAPLUS
Cody	1992	52	315	J Surg Res	
Dintzis	1993	16	306	Proteins	HCAPLUS
Dugas	1981		54	Bioorganic Chemistry	
Dunn	1985	98	283	Surgery	MEDLINE
Elsbach	1993			US 5198541	HCAPLUS
Elsbach	1993	5	103	Current Opinion in I	HCAPLUS
Farley	1988	56	1589	Infect Immun	HCAPLUS
Gabay	1989	86	5610	Proc Nat'l Acad Sci	HCAPLUS
Gallin	1983	99	657	Ann Int Med	MEDLINE
Gazzano-Santoro	1992	60	4754	Infect Immun	HCAPLUS
Gray	1989	264	9505	J Biol Chem	HCAPLUS
Hancock	1984	38	237	Ann Rev Microbiol	HCAPLUS
Hartree	1972	48	422	Anal Biochem	HCAPLUS
Little	1994			US 5348942	HCAPLUS
Marra	1992			US 5089274	HCAPLUS
Scott	1992			US 5171739	HCAPLUS
Scott	1994			US 5334584	HCAPLUS

L31 ANSWER 44 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:678705 HCAPLUS
DN 130:34902
TI Binding of the cysteine proteinases papain and cathepsin B-like to coated laminin: use of synthetic peptides from laminin and from the laminin binding region of the β1 **integrin** subunit to characterize the binding site
AU Dalet-Fumeron, Veronique; Boudjennah, Laziz; Pagano, Maurice
CS Biochimie des Proteases, Faculte de Medecine Broussais Hotel-Dieu, Universite Pierre et Marie Curie, Paris, 75270, Fr.
SO Archives of Biochemistry and Biophysics (**1998**), 358(2), 283-290
CODEN: ABBIA4; ISSN: 0003-9861
PB Academic Press
DT Journal
LA English
AB Cysteine proteinases of the papain superfamily, i.e., papain and cathepsin B-like proteinase, were found to be able to bind to laminin-coated wells. When papain and cathepsin B-like proteinase were used, saturable binding curves were found. The characterization of the binding site was carried out using synthetic peptides which corresponded to the most relevant functional sites of laminin and an octapeptide from the laminin binding region of the β1 **integrin** subunit. In binding expts., the decapeptide RNIAEIIRDI and the pentapeptide YIGSR were able to displace papain and cathepsin B-like proteinase from coated laminin. Nevertheless, the **integrin** β1 peptide DLYYLMDL was the most powerful in the same exptl. system. From these results, the C-terminal region of this cross-shaped protein, i.e., the end of the long arm, and the region including the YIGSR sequence of the short arm of the β chain would be the cysteine proteinase binding site. This binding site is probably the result of the network organization of laminin which brings two regions, separated on a single laminin mol., into proximity. In previous work, digestion of basement membranes has been found to be associated with the binding of cysteine proteinases to these supramol. structures [N. Guinec, V. Dalet-Fumeron, and M. Pagano (1992) FEBS Lett. 308, 305-308]. The present report demonstrates that laminin is the cysteine proteinase

binding protein of basement membranes. This property of laminin could be associated with tumor invasion and other tissue remodeling processes linked to proteolysis of basement membranes and extracellular matrixes. (c) 1998 Academic Press.

IT **146439-94-3**
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(binding of cysteine proteinases papain and cathepsin B-like to laminin coated wells used to characterize the binding site)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Ardini, E	1997	272	2342	J Biol Chem	HCAPLUS
Aumailley, M	1989	184	241	Eur J Biochem	HCAPLUS
Barrett, A	1992	674	1	Ann N Y Acad Sci	HCAPLUS
Berti, P	1995	246	273	J Mol Biol	HCAPLUS
Dalet-Fumeron, V	1996	335	351	Arch Biochem Biophys	HCAPLUS
Dalet-Fumeron, V	1993	332	251	FEBS Lett	HCAPLUS
Engel, J	1992	31	10643	Biochemistry	HCAPLUS
Gehlsen, K	1992	117	449	J Cell Biol	HCAPLUS
Grant, D	1992	153	614	J Cell Physiol	HCAPLUS
Guinec, N	1990	371	239	Biol Chem Hoppe-Seyl	
Guinec, N	1993	374	1135	Biol Chem Hoppe-Seyl	HCAPLUS
Guinec, N	1992	308	305	FEBS Lett	HCAPLUS
Hadman, M	1996	12	135	Oncogene	HCAPLUS
Hogervorst, F	1990	9	765	EMBO J	HCAPLUS
Hunter, I	1990	188	205	Eur J Biochem	HCAPLUS
Illy, C	1997	272	1197	J Biol Chem	HCAPLUS
Iwamato, Y	1987	238	1132	Science	
Iwamoto, Y	1996	73	589	Br J Cancer	HCAPLUS
Iwamoto, Y	1988	134	287	J Cell Physiol	HCAPLUS
Keppler, D	1988	369	185	Biol Chem Hoppe-Seyl	
Liesi, P	1989	244	141	FEBS Lett	HCAPLUS
Lipps, G	1996	271	1717	J Biol Chem	HCAPLUS
Mac Dougall, J	1995	14	351	Cancer Metastasis Re	HCAPLUS
Mignatti, P	1993	73	161	Physiol Rev	HCAPLUS
Mort, J	1981	662	173	Biochim Biophys Acta	HCAPLUS
Moser, T	1993	268	18917	J Biol Chem	HCAPLUS
Musil, D	1991	10	2321	EMBO J	HCAPLUS
Pagano, M	1986	64	1218	Biochem Cell Biol	HCAPLUS
Pagano, M	1989	45	13	Cancer Lett	HCAPLUS
Pagano, M	1995		3	Proteases Involved i	
Qian, F	1994	202	429	Biochem Biophys Res	MEDLINE
Sloane, B	1994	2	411	Biochemical and Mole	HCAPLUS
Timpl, R	1996	8	618	Curr Opin Cell Biol	HCAPLUS
Vlodavsky, I	1990	9	203	Cancer Metastasis Re	MEDLINE
Yurchenco, P	1994	6	674	Curr Opin Cell Biol	HCAPLUS
Ziober, B	1996	7	119	Semin Cancer Biol	HCAPLUS

L31 ANSWER 45 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:590656 HCAPLUS
DN 129:229676
TI Modified antibodies with human milk fat globule specificity for breast cancer diagnosis and therapy
IN Do Couto, Fernando J. R.; Ceriani, Roberto L.; Peterson, Jerry A.
PA Cancer Research Fund of Contra Costa, USA
SO U.S., 76 pp., Cont.-in-part of U.S. Ser. No. 977,696.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 2
PATENT NO. KIND DATE APPLICATION NO. DATE

PI	US 5804187	A	19980908	US 1993-129930	19930930 <--
	US 5792852	A	19980811	US 1992-977696	19921116 <--
	CA 2149529	AA	19940526	CA 1993-2149529	19931116 <--
	WO 9411509	A2	19940526	WO 1993-US11445	19931116 <--
	WO 9411509	A3	19940707		
	W: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9463964	A1	19940608	AU 1994-63964	19931116 <--
	EP 674710	A1	19951004	EP 1994-903300	19931116 <--
	EP 674710	B1	20030502		
	R: DE, ES, FR, GB, IE, IT, NL, SE				
	JP 09503901	T2	19970422	JP 1993-512520	19931116 <--
	US 6315997	B1	20011113	US 1997-976288	19971121 <--
	US 2003138428	A1	20030724	US 2001-947839	20010906 <--
PRAI	US 1992-977696	A2	19921116 <--		
	US 1993-129930	A	19930930 <--		
	US 1993-134346	A	19931008 <--		
	WO 1993-US11445	W	19931116 <--		
	US 1997-976288	A3	19971121 <--		

AB An analog peptide that comprises the variable regions of the light or heavy chains of an antibody of a first species selectively binding to a carcinoma antigen has 1 to 46 amino acids of the framework regions per chain substituted with amino acids such as those present in equivalent positions in antibodies of a species other than the first species, or fragments thereof comprising 1 to 3 variable region CDRs per chain and optionally flanking regions thereof of 1 to 10 or more amino acids, alone or with an N-terminal fragment of 1 to 10 or more amino acids, combinations or mixts. thereof. The polypeptide may also comprise an effector agent and/or be glycosylated, and is presented as a composition with a carrier. The analog peptides are used in diagnostic kits for carcinomas and methods for in vivo imaging and treating a primary or metastasized carcinoma, and in vitro diagnosing a carcinoma, ex vivo purging neoplastic cells from a biol. fluid. RNAs and DNAs encode the analog peptide, and a hybrid vector carrying the nucleotides and transfected cells express the peptides and a method produces the analog peptide. An anti-idiotype polypeptide comprises polyclonal antibodies raised against an anti-carcinoma antibody or the analog peptide of this invention, monoclonal antibodies thereof, Fab, Fab', (Fab')2, CDR, variable region, or analogs or fragments thereof, combinations thereof with an oligopeptide comprising a TRP trimer, tandem repeats thereof, or combination or mixts. thereof. An anti-idiotype hybrid polypeptide with an effector agent and the anti-idiotype polypeptide, an anti-carcinoma vaccine, an anti-carcinoma vaccination kit, a method of vaccinating against carcinoma and a method of lowering the serum concentration of a circulating antibody or polypeptide are provided.

IT **157414-67-0P**
RL: BPN (Biosynthetic preparation); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PREP (Preparation); PROC (Process)
(modified antibodies with human milk fat globule specificity for breast cancer diagnosis and therapy)

RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File
Anon	1988			GB 2188638	HCAPLUS
Anon	1990			WO 907861	
Anon	1991			WO 9109967	HCAPLUS
Anon	1992			WO 9204380	HCAPLUS
Baggiolini	1990		69	No publication given	HCAPLUS

Bhat	1990	347	483	Nature	HCAPLUS
Bhat		91	1089	Proc Natl Acd Sci (U	HCAPLUS
Bowie	1990	24	1306	Science	
Brady	1992	227	253	J Mol Biol	HCAPLUS
Burton, D	1990		64	Antibody:the	HCAPLUS
Ceriani	1991			US 5075219	
Ceriani	1991			US 5077220	
Co And Queen	1991	351	501	Nature	
Couto, J	1994	13	215	Hybridoma	HCAPLUS
Cunningham	1992	10	112	Tibtech	MEDLINE
Davies	1992	2	254	Current Biology	HCAPLUS
Davies, D	1990	59	439	Annu Rev Biochem	HCAPLUS
Delves, P	1992		207	Encyclopedia of Immu	
Eigenbrot	1994	18	49	Proteins:Structure,	HCAPLUS
Fischmann	1991	266	12915	J Bio Chem	HCAPLUS
Harris	1993	11	42	Tibtech	MEDLINE
Hird	1990		183	Genes and Cancer	
Huber	1987	326	334	Nature	MEDLINE
Kettleborough	1991	4	773	Protein Eng	HCAPLUS
Kortright	1987			US 4708930	
Morrison	1988		187	Genetic engineering	HCAPLUS
Neuberger	1984	312	604	Nature	HCAPLUS
Peterson, J	1990	9	221	Hybridoma	MEDLINE
Presta	1993	151	2623	Jour of Immuno	HCAPLUS
Richard, F	1987	326	335	Nature	
Riechmann, L	1988	332	323	Nature	HCAPLUS
Steiner, L	1983	5	973	Bioscience Reports	
Tempest	1991	9	266	Biotechnology	MEDLINE
Varhoeyen	1988	239	1534	Science	
Vitetta	1987	238	1098	Science	HCAPLUS

L31 ANSWER 46 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:457248 HCAPLUS
DN 129:104211
TI Platelet factor 4-related anti-inflammatory peptides
IN Counts, David F.; Duff, Ronald G.
PA Curative Health Services, Inc., USA
SO U.S., 55 pp., Cont.-in-part of U. S. Ser. No. 80,371, abandoned.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE		APPLICATION NO.	DATE
PI	US 5776892	A	19980707		US 1994-259550	19940616 <--
	US 5470831	A	19951128		US 1993-37486	19930324 <--
PRAI	US 1990-631823	B1	19901221	<--		
	US 1993-37486	A2	19930324	<--		
	US 1993-80371	B2	19930618	<--		

OS MARPAT 129:104211
AB Peptides, peptide analogs and peptide derivs. related to platelet factor 4 are disclosed which exhibit anti-inflammatory activity, as are pharmaceutical compns. comprising the peptides and methods of inhibiting inflammation using the peptides.
IT **210093-16-6**
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(platelet factor 4-related anti-inflammatory peptides)
RETABLE

Referenced Author (RAU)	Year (RPY)	VOL (RVL)	PG (RPG)	Referenced Work (RWK)	Referenced File

Anon	1990			EP 0378364	HCAPLUS
Anon	1992			WO 9211021	HCAPLUS
Banda	1982	79	7773	Proc Natl Acad Sci U	HCAPLUS
Barone	1991	29	336	J Neurosci Res	MEDLINE
Bebawy	1986	39	423	J Leukocyte Biol	HCAPLUS
Bernstein	1982	56	71	J Cell Sci	HCAPLUS
Blackwell	1980	287	147	Nature	HCAPLUS
Borovsky	1994			US 5358934	HCAPLUS
Brown	1992			US 5141851	HCAPLUS
Browne	1976	143	738	Surg Gynecol Obstet	MEDLINE
Broxmeyer	1993	150	3448	J Immunol	HCAPLUS
Cella	1986	113	646	Folia Haematol	MEDLINE
Ciaglowski	1986	250	249	Arch Biochem and Bio	HCAPLUS
Cortellaro	1990	58	571	Thromb Res	MEDLINE
Diezel	1989	93	322	J Invest Dermatol	HCAPLUS
Doherty	1988	91	298	J Invest Derm	HCAPLUS
Edgington	1993	11	676	Bio/Technol	HCAPLUS
Eisman	1990	76	336	Blood	HCAPLUS
Filipp	1984	39	499	Allergy	HCAPLUS
Freidinger	1987			US 4703034	HCAPLUS
Fuhrer	1988			US 4719288	HCAPLUS
Gimbrone	1974	52	413	J Nat'l Cancer Inst	
Griswold	1991	42	825	Biochem Pharmacol	HCAPLUS
Guastamacchia	1985	61	499	Boll Soc It Biol	MEDLINE
Hahn	1989			US 4816449	HCAPLUS
Hanna	1990	16	137	Drugs Exptl Clin Res	HCAPLUS
Johansson	1993	73	401	Acta Derm Venereol (	MEDLINE
Johansson	1994	74	106	Acta Derm Venereol (	MEDLINE
Konishi	1984			US 4461724	HCAPLUS
Kragballe	1985	13	1	Curr Probl Derm	MEDLINE
Kuna	1995			US 5436222	HCAPLUS
Maione	1992			US 5086164	HCAPLUS
Medici	1989	54	277	Thromb Res	HCAPLUS
Morgan	1986			US 4585755	HCAPLUS
Obal	1990	259	R439	Am J Physiol	HCAPLUS
Rybak	1989	73	1534	Blood	HCAPLUS
Schmitz-Huebner	1984	34	277	Thromb Res	MEDLINE
Twardzik	1987			US 4645828	HCAPLUS
Verdini	1989			US 4816560	HCAPLUS
Weerasinghe	1984	33	625	Thromb Res	HCAPLUS
Wei	1993	33	91	Annu Rev Pharmacol T	HCAPLUS
Whitman	1995			US 5470831	HCAPLUS
Widmer	1995			US 5411942	HCAPLUS
Wiedeman	1995			US 5386011	HCAPLUS
Wooley	1988	162	361	Meth Enzym	HCAPLUS
Young	1984	82	367	J Invest Derm	HCAPLUS
Zucker	1989	86	7571	Proc Natl Acad Sci U	HCAPLUS

L31 ANSWER 47 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:411084 HCAPLUS
DN 127:120702
TI Synthetic peptides containing B- and T-cell epitopes of human immunodeficiency virus 1 proteins
IN Sia, Charles D. Y.; Chong, Pele; Klein, Michel H.
PA Connaught Laboratories Limited, Can.
SO U.S., 41 pp., Cont.-in-part of U.S. Ser. No. 73,378, abandoned.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5639854	A	19970617	US 1994-257528	19940609 <--

CN 1128538	A	19960807	CN 1994-192854	19940608	<--
CN 1111540	B	20030618			
US 5759769	A	19980602	US 1995-460602	19950602	<--
US 5795955	A	19980818	US 1995-463966	19950605	<--
US 5800822	A	19980901	US 1995-465217	19950605	<--
US 5817754	A	19981006	US 1995-464329	19950605	<--
US 5876731	A	19990302	US 1995-462507	19950605	<--
US 5951986	A	19990914	US 1995-467881	19950606	<--
PRAI US 1993-73378	B2	19930609	<--		
US 1994-257528	A3	19940609	<--		

AB Synthetic peptides for use in vaccines against HIV-1 and in diagnostic applications are described. The peptides include a T-cell epitope of a gag protein, specifically p24E linked directly to a B-cell epitope of the V3 loop of an HIV-1 isolate and containing the sequence GPGR, and/or the gp41 containing the sequence ELKDWA. Proteins containing multimers of such sequences are described. A panel of peptides was synthesized and characterized using guinea pigs.

IT **136338-41-5**
RL: PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); USES (Uses)
(amino acid sequence, as antigen in vaccine against HIV-1; synthetic peptides containing B- and T-cell epitopes of human immunodeficiency virus 1 proteins)

L31 ANSWER 48 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:219630 HCAPLUS
DN 126:304022
TI Role of laminin in matrix induction of macrophage urokinase-type plasminogen activator and 92-kDa metalloproteinase expression
AU Khan, K. M. Faisal; Falcone, Domenick J.
CS Dep. Pathol., Cornell Univ. Med. Coll., New York, NY, 10021, USA
SO Journal of Biological Chemistry (**1997**), 272(13), 8270-8275
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English
AB Urokinase-type plasminogen activator (uPA) and 92-kDa matrix metalloproteinase (MMP-9) expression by RAW264.7 macrophages were up-regulated when plated on extracellular matrixes. Collagen IV, fibronectin, and tenascin stimulated macrophages' MMP-9 expression. In contrast, laminin stimulated both uPA and MMP-9 expression in a dose- and time-dependent manner. The increase in macrophage uPA activity was preceded by an increase in their steady state levels of uPA mRNA. Laminin-induced uPA expression was most pronounced in RAW264.7 macrophages followed by THP-1 monocytes, J774A.1 macrophages, and bone marrow-derived macrophages. Neither laminin nor matrix induced alterations in THP-1 monocyte expression of plasminogen activator inhibitor, tissue inhibitor of metalloproteinase (TIMP)-1 or TIMP-2. Synthetic laminin peptides were utilized to identify the laminin domain(s) responsible for induction of uPA expression. Peptides derived from the β1 chain of laminin had no effect on macrophage uPA expression, whereas SIKVAV, derived from α1 chain, stimulated uPA expression 20-fold. Preincubation of THP-1 monocytes with a monoclonal antibody directed against the α6 subunit of the α6β1 laminin receptor blocked matrix induction of uPA without affecting the induction of MMP-9. These results demonstrate that macrophage binding to laminin plays an important role in the regulation of their degradative phenotype via the up-regulation of uPA and MMP-9.

IT **146439-94-3**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(role of laminin in matrix induction of macrophage urokinase-type plasminogen activator and 92-kDa metalloproteinase expression)

L31 ANSWER 49 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:204132 HCAPLUS
DN 126:199836
TI Cyclic dimeric peptide inhibitors of fibronectin for treatment of rheumatoid arthritis, asthma, and multiple sclerosis.
IN Dutta, Anand Swaroop
PA Zeneca Limited, UK; Dutta, Anand Swaroop
SO PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9702289	A1	19970123	WO 1996-GB1580	19960702 <--
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA				
	AU 9663119	A1	19970205	AU 1996-63119	19960702 <--
	EP 842195	A1	19980520	EP 1996-922132	19960702 <--
	R: CH, DE, FR, GB, IT, LI				
	JP 11508583	T2	19990727	JP 1996-504917	19960702 <--
	ZA 9605738	A	19970106	ZA 1996-5738	19960705 <--
	US 6034057	A	20000307	US 1998-981680	19980106 <--
PRAI	GB 1995-13798	A	19950706 <--		
	GB 1996-11470	A	19960601 <--		
	WO 1996-GB1580	W	19960702 <--		

OS MARPAT 126:199836
GI



AB Cyclic dimeric peptides I and II (A1 = D- or L-Ile, D- or L-Leu, or analogs; A2 = Leu or analogs; A3 = Asp, Glu, or analogs; A4 = Val or analogs; L1 and L2 independently represent linking moieties to form a cyclic peptide) or their salts were prepared Thus, II (A1-A2-A3-A4 = Ile-Leu-Asp-Val; L1 = L2 = piperazinyl-1-yl-acetyl) was prepared by the solid phase method on 2-chlorotrityl chloride resin using HBTU and diisopropylethylamine for peptide coupling and cyclization of the linear peptides. The cyclic dipeptides I and II inhibit the interaction of vascular cell adhesion mol.-1 (VCAM-1) and fibronectin with **integrin** very late antigen 4 and are claimed for treatment of rheumatoid arthritis, asthma or multiple sclerosis (no data).
IT **187618-44-6DP**, chlorotrityl resin-bound **187618-45-7P** **187618-46-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of cyclic dimeric peptide inhibitors of fibronectin for treatment of rheumatoid arthritis, asthma, and multiple sclerosis)

L31 ANSWER 50 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:467371 HCAPLUS
DN 125:151136
TI Fimbrial polypeptides useful in the prevention of periodontitis
IN Evans, Richard T.; Bedi, Gurrinder S.; Genco, Robert J.; Sojar, Hakimuddin T.
PA State University of New York, USA
SO U.S., 23 pp.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 5536497	A	19960716	US 1992-994277	19921221 <--
PRAI US 1992-994277		19921221 <--		

AB Polypeptides related to fimbriae of Porphyromonas gingivalis are described and claimed which exhibit inhibition of bacterial adhesion to saliva-coated surfaces. The polypeptides are selected from the group consisting of fimbriae, fimbrillin, and fimbrial-related. peptides derived therefrom. The polypeptides are used as active ingredients in various oral formulations designed to prevent adhesion of P. gingivalis to host mucosal surfaces and thus interfering with the development of periodontitis. The polypeptides are also used in subunit vaccine formulations for use against pathogenic, fimbriated P. gingivalis in the prophylactic treatment of periodontitis. Use of the polypeptides for inducing protective immunity in serum and gingival crevicular fluid may prevent primary infection with P. gingivalis as well as the spread of the organism between intraoral reservoirs.
IT **179953-78-7P**
RL: **BAC (Biological activity or effector, except adverse)**; BSU (Biological study, unclassified); PNU (Preparation, unclassified); PRP (Properties); **THU (Therapeutic use)**; BIOL (Biological study); PREP (Preparation); USES (Uses)
(fimbrial polypeptides useful in the prevention of periodontitis)

L31 ANSWER 51 OF 51 HCAPLUS COPYRIGHT 2004 ACS on STN
AN 1988:505563 HCAPLUS
DN 109:105563
TI Antigenic modification of polypeptides, especially peptides of human chorionic gonadotropin (HCG)
IN Stevens, Vernon C.
PA Ohio State University, USA
SO U.S., 56 pp. Cont.-in-part of U.S. 4,526,716.
CODEN: USXXAM
DT **Patent**
LA English
FAN.CNT 7

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 4691006	A	19870901	US 1984-667863	19841102 <--
BE 814684	A1	19741107	BE 1974-144040	19740507 <--
ZA 7402897	A	19751231	ZA 1974-2897	19740507 <--
ES 426043	A1	19761116	ES 1974-426043	19740507 <--
SU 683603	D	19790830	SU 1974-2022657	19740507 <--
IL 50668	A1	19800331	IL 1976-50668	19761012 <--
US 4201770	A	19800506	US 1978-936876	19780825 <--
CA 1085383	A2	19800909	CA 1979-324452	19790329 <--
US 4302386	A	19811124	US 1980-112628	19800116 <--
US 4384995	A	19830524	US 1981-323690	19811120 <--
US 4526716	A	19850702	US 1983-472190	19830304 <--
WO 8403443	A1	19840913	WO 1983-US777	19830518 <--

W: AU, DK, FI, GB, HU, JP, NO, RO, SU, US

```
     US 4762913        A    19880809       US 1987-73769    19870715 <--
     US 5006334        A    19910409       US 1987-73748    19870715 <--
     US 5698201        A    19971216       US 1995-468716   19950606 <--
     US 6039948        A    20000321       US 1995-469043   19950606 <--
     US 6096318        A    20000801       US 1995-466445   19950606 <--
     US 6143305        A    20001107       US 1995-471422   19950606 <--
     US 6146633        A    20001114       US 1995-466660   19950606 <--
PRAI US 1973-357892    A2   19730507  <--
     US 1973-406821    A2   19731016  <--
     US 1974-462955    A2   19740422  <--
     US 1975-622031    A2   19751014  <--
     US 1978-936876    A3   19780825  <--
     US 1980-112628    A2   19800116  <--
     US 1981-323690    A2   19811120  <--
     US 1983-472190    A2   19830304  <--
     WO 1983-US777     A2   19830518  <--
     CA 1974-199003    A3   19740506  <--
     IL 1974-44779     A    19740507  <--
     US 1981-112628    A2   19810116  <--
     US 1984-667863    A3   19841102  <--
     US 1987-73748     A3   19870715  <--
     US 1989-311331    B1   19890217  <--
     US 1992-935331    A3   19920826  <--
AB   Endogenous and exogenous proteins and their fragments are chemical modified
     outside the body of an animal so that when injected into the animal they
     produce more antibodies against the unmodified protein than would
     injection of the unmodified protein or fragment alone.  The proteins (e.g.
     FSH, HCG) are modified by attachment of carriers, e.g. bacterial toxoids,
     or by polymerization of protein fragments.  The modified polypeptides are
     administered to animals for contraception, abortion, and treatment of
     hormone-associated carcinomas.  Synthetic polypeptides corresponding to 12-16
     amino acid residue portions of β-HCG were conjugated to diphtheria
     toxoid (30 mols. peptide/100 kdalton toxoid) and injected with Complete
     Freund's Adjuvant into rabbits.  Antibody levels of 15.70, 100.45, 75.70,
     and 0.44 were found for peptide sequences 30-42, 110-122, 130-145, and
     100-112, resp. (highest and lowest values).
IT   116088-06-3D, diphtheria toxoid conjugates
     RL: BIOL (Biological study)
        (vaccine containing, antibody response to)


=> => d his l32-

     (FILE 'HCAPLUS' ENTERED AT 07:52:55 ON 08 APR 2004)
                SEL HIT RN L31

     FILE 'REGISTRY' ENTERED AT 07:55:21 ON 08 APR 2004
L32           89 S E1-E89
                SAV L32 HADDAD030A/A
L33           89 S L32 AND L8

=> fil reg
FILE 'REGISTRY' ENTERED AT 07:55:58 ON 08 APR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:     6 APR 2004  HIGHEST RN 672263-62-6
DICTIONARY FILE UPDATES:    6 APR 2004  HIGHEST RN 672263-62-6
```

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d sqide can 1 10 20 30 40 50 60 70 80 89

L33 ANSWER 1 OF 89 REGISTRY COPYRIGHT 2004 ACS on STN
RN **651760-31-5** REGISTRY
CN L-Isoleucine, L-asparaginyl-L-alanyl-L-arginyl-L-lysyl-L-isoleucyl-L-seryl-
L-valyl-L-lysyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 9

SEQ 1 NARKISVKI
=========
HITS AT: 1-9
MF C45 H85 N15 O12
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:176291

L33 ANSWER 10 OF 89 REGISTRY COPYRIGHT 2004 ACS on STN
RN **495392-44-4** REGISTRY
CN L-Leucine, L-prolyl-L-arginyl-L-leucyl-L-alanyl-L-glutaminyl-L-leucyl-L-arginyl-L-leucyl-L-leucyl-L-seryl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 441: PN: US20030028003 SEQID: 441 unclaimed sequence
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 11

PATENT ANNOTATIONS (PNTE):

Sequence Source	Patent Reference
Not Given	US2003028003 unclaimed SEQID 441

SEQ 1 PRLAQLRLLS L
========== =
HITS AT: 1-11
MF C58 H106 N18 O14
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B

—NH_2

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 138:148752

L33 ANSWER 20 OF 89 REGISTRY COPYRIGHT 2004 ACS on STN
RN **475163-95-2** REGISTRY
CN L-Valine, L-lysyl-L-leucyl-L-alanyl-L-cysteinyl-L-α-aspartyl-L-α-aspartyl-L-isoleucyl-L-arginyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 59: PN: US20030091562 SEQID: 59 unclaimed sequence
CN 93: PN: US20030213004 SEQID: 90 claimed sequence
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 9

PATENT ANNOTATIONS (PNTE):

Sequence Source	Patent Reference
Not Given	US2003091562 unclaimed SEQID 59

SEQ 1 KLACDDIRV
=========
HITS AT: 1-9
MF C43 H77 N13 O14 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1907 TO DATE)
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 139:376231

REFERENCE 2: 138:400391

REFERENCE 3: 138:1114

L33 ANSWER 30 OF 89 REGISTRY COPYRIGHT 2004 ACS on STN
RN **355838-88-9** REGISTRY
CN L-Isoleucine, L-leucyl-L-methionyl-L-cysteinyl-L-valyl-L-α-aspartyl-L-valyl-L-lysyl-L-leucyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 39: PN: US20030223973 SEQID: 39 unclaimed sequence
CN 3: PN: US20020142317 SEQID: 39 unclaimed sequence
CN 41: PN: US6294344 SEQID: 39 unclaimed sequence
CN 42: PN: WO0159158 SEQID: 39 unclaimed sequence
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 9

PATENT ANNOTATIONS (PNTE):

Sequence Source	Patent Reference
Not Given	US6294344 unclaimed SEQID 39
	WO2001059158 unclaimed SEQID 39

SEQ 1 LMCVDVKLI
HITS AT: 1-9
MF C46 H84 N10 O12 S2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:19794

REFERENCE 2: 137:274034

REFERENCE 3: 135:271299

REFERENCE 4: 135:193984

L33 ANSWER 40 OF 89 REGISTRY COPYRIGHT 2004 ACS on STN
RN **321522-53-6** REGISTRY
CN L-Phenylalanine, L-phenylalanyl-L-glutaminylglycyl-L-valyl-L-alanyl-L-α-glutamyl-L-asparaginyl-L-valyl-L-arginyl-L-phenylalanyl-L-valyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 12

SEQ 1 FQGVAENVRF VF
========== ==
HITS AT: 1-12
MF C67 H97 N17 O17
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:110451

L33 ANSWER 50 OF 89 REGISTRY COPYRIGHT 2004 ACS on STN
RN **256651-29-3** REGISTRY
CN Peptide, (Xaa-Xaa-Ser-Leu-Arg-Phe) (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 11: PN: US6020312 SEQID: 19 claimed protein
FS PROTEIN SEQUENCE
SQL 6
NTE

type	------ location ------		description
uncommon	Aaa-1	-	-
uncommon	Aaa-2	-	-

PATENT ANNOTATIONS (PNTE):
Sequence |Patent

Source	Reference
Not Given	US6020312 claimed SEQID 19

SEQ 1 XXSLRF
      ======
HITS AT: 1-6
MF Unspecified
CI MAN
SR CA
LC STN Files: CA, CAPLUS, USPATFULL
1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 132:146627

L33 ANSWER 60 OF 89 REGISTRY COPYRIGHT 2004 ACS on STN
RN **247111-68-8** REGISTRY
CN L-Phenylalanine, L-phenylalanyl-L-alanylglycyl-L-valyl-L-leucyl-L-glutaminyl-L-asparaginyl-L-valyl-L-arginyl-L-phenylalanyl-L-valyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 12

SEQ 1 FAGVLQNVRF VF
      ========== ==
HITS AT: 1-12
MF C68 H101 N17 O15
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 134:110451

REFERENCE 2: 131:296707

L33 ANSWER 70 OF 89 REGISTRY COPYRIGHT 2004 ACS on STN
RN **238087-65-5** REGISTRY
CN L-Isoleucine, L-cysteinyl-L-prolyl-L-seryl-L-isoleucyl-L-arginyl-L-isoleucyl-L-threonyl-L-seryl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 19: PN: US20040002117 SEQID: 19 unclaimed sequence
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 9

PATENT ANNOTATIONS (PNTE):

Sequence Source	Patent Reference
Not Given	US2004002117 unclaimed SEQID 19

SEQ 1 CPSIRITSI
========
HITS AT: 1-9
MF C42 H76 N12 O13 S
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

Absolute stereochemistry.



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 140:82214

REFERENCE 2: 131:165306

L33 ANSWER 80 OF 89 REGISTRY COPYRIGHT 2004 ACS on STN
RN **187618-46-8** REGISTRY
CN L-Valine, N5-[[[(2,3-dihydro-2,2,4,6,7-pentamethyl-5-benzofuranyl)sulfonyl]amino]iminomethyl]-D-ornithyl-N-methyl-L-isoleucyl-L-leucyl-L-α-aspartyl-L-valyl-N5-[[[(2,3-dihydro-2,2,4,6,7-pentamethyl-5-benzofuranyl)sulfonyl]amino]iminomethyl]-D-ornithyl-N-methyl-L-isoleucyl-L-leucyl-L-α-aspartyl-, 4,9-bis(1,1-dimethylethyl) ester, monohydrochloride (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 10
NTE modified (modifications unspecified)

type	------ location ------		description
modification	-	-	undetermined modification
modification	Arg-1	-	undetermined modification
modification	Ile-2	-	methyl<Me>
modification	Asp-4	-	1,1-dimethylethyl<t-Bu>
modification	Arg-6	-	undetermined modification
modification	Ile-7	-	methyl<Me>
modification	Asp-9	-	1,1-dimethylethyl<t-Bu>

SEQ 1 RILDVRILDV
==========
HITS AT: 1-10

RELATED SEQUENCES AVAILABLE WITH SEQLINK
MF C90 H150 N16 O21 S2 . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL

CRN (187618-44-6)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 126:199836

L33 ANSWER 89 OF 89 REGISTRY COPYRIGHT 2004 ACS on STN
RN **116088-06-3** REGISTRY
CN L-Cysteine, L-arginyl-L-α-aspartyl-L-valyl-L-arginyl-L-phenylalanyl-L-α-glutamyl-L-seryl-L-isoleucyl-L-arginyl-L-leucyl-L-prolylglycyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 5: PN: US6331610 SEQID: 5 claimed sequence
CN 60-72-Chorionic gonadotropin (human subunit β)
CN 60-72-Chorionic gonadotropin β-subunit (human)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 13

PATENT ANNOTATIONS (PNTE):

Sequence Source	Patent Reference
Not Given	US6331610 claimed SEQID 5

SEQ 1 RDVRFESIRL PGC

HITS AT: 1-13
MF C66 H110 N22 O19 S
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-B

3 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 136:48813

REFERENCE 2: 127:229764

REFERENCE 3: 109:105563

=>